checkAd

    DNAG-PRINT - 500 Beiträge pro Seite

    eröffnet am 03.01.07 13:09:33 von
    neuester Beitrag 09.01.08 18:05:33 von
    Beiträge: 335
    ID: 1.103.108
    Aufrufe heute: 0
    Gesamt: 20.976
    Aktive User: 0

    ISIN: US23324Q2021 · WKN: A0ETWM · Symbol: DNAG
    0,0000
     
    USD
    0,00 %
    0,0000 USD
    Letzter Kurs 29.02.24 Nasdaq OTC

    Werte aus der Branche Biotechnologie

    WertpapierKursPerf. %
    3,0700+88,34
    1,0800+69,01
    4,9000+44,12
    5,0000+43,68
    0,9500+34,94
    WertpapierKursPerf. %
    1,8300-18,30
    2,1000-18,92
    5,2600-29,40
    2,0400-35,44
    3,5100-46,00

     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 03.01.07 13:09:33
      Beitrag Nr. 1 ()
      Auf ein Erfolgreiches Neues Jahr mit DNAG

      http://www.amalfiresearch.com/report/DNAG.pdf
      Avatar
      schrieb am 03.01.07 13:22:18
      Beitrag Nr. 2 ()
      Antwort auf Beitrag Nr.: 26.653.419 von Qork am 03.01.07 13:09:33



      Avatar
      schrieb am 03.01.07 14:13:21
      Beitrag Nr. 3 ()
      super gute arbeit...dnag wird seinen weg gehen...

      ich bin dabei...

      liebe grüße
      svenja
      Avatar
      schrieb am 03.01.07 14:14:42
      Beitrag Nr. 4 ()
      der research bericht ist super gut zu lesen....
      ein prosit auf dnag !!

      weiter einsteigen...

      ps: wer erklärt mir den absturz von 0,03 auf jetzt 0,095 us$.
      danke
      Avatar
      schrieb am 03.01.07 14:15:21
      Beitrag Nr. 5 ()
      Antwort auf Beitrag Nr.: 26.654.509 von brokersvenja007 am 03.01.07 14:14:42der research bericht ist super gut zu lesen....
      ein prosit auf dnag !!

      weiter einsteigen...

      ps: wer erklärt mir den absturz von 0,03 auf jetzt 0,0095 us$(!!!!)danke

      Trading Spotlight

      Anzeige
      Nurexone Biologic
      0,5400EUR +11,11 %
      Technisches (täglich, wöchentlich, monatlich) & Analysten “Strong Buy”-Rating!mehr zur Aktie »
      Avatar
      schrieb am 03.01.07 14:38:32
      Beitrag Nr. 6 ()
      Antwort auf Beitrag Nr.: 26.654.522 von brokersvenja007 am 03.01.07 14:15:21Ich nehme an weil sich der Float von 150 Mio auf heute 400 Mio sich erhöht hat.
      Aber ich bin hier Long eingestellt.
      Biofrontera hat ein gutes Produkt das sich in der 3ten Testphase befindet.
      Avatar
      schrieb am 03.01.07 15:38:13
      Beitrag Nr. 7 ()
      :kiss::kiss::kiss::kiss::kiss::kiss:
      Avatar
      schrieb am 03.01.07 15:43:22
      Beitrag Nr. 8 ()
      Antwort auf Beitrag Nr.: 26.654.522 von brokersvenja007 am 03.01.07 14:15:21svenja, das mit dem Absturz hat schon eine viel längere Geschichte hinter sich als "nur" von 0,03 runter.
      Nach einem langjährigen Downtrend gingen der Company allmählich die Aktien aus.
      Deshalb hat sie im Sommer 2005 einen Resplit 1 für 20 beschlossen und durchgeführt. Danach war der Kurs rechnerisch zwar wieder oben, so etwa bei 0,12 aber dann passierte das, was erfahrungsgemäß immer nach einem Resplit passiert: Der Kurs ging wieder runter.

      Der Grund dafür ist ziemlich klar: So lange die Firma wesentlich geringere Einkünfte hat als laufende Ausgaben, so lange muss die Firma sich durch Verkauf eigener Aktien finanzieren, also Erhöhung des Floats, also Verwässerung der Anteile der Alt-Eigentümer, also ein Niedergang des Kurses!

      Da nützt es auch nichts, wenn aufgrund irgendeiner guten Nachricht allgemein eine große Begeisterung ausbricht, der Kurs ein Stück nach oben schießt und diverse hiesige User zum schnellen Einstieg jubeln! (Anwesende sind von meiner Kritik natürlich ausgenommen ;) )

      An der grundsätzlichen Art der Finanzierung muss sich was ändern!
      Ein dauerhafter Umsatzträger muss her!
      Was mich ein wenig optimistisch stimmt: In den letzten Tagen hat sich der Kurs recht wacker geschlagen.
      Vielleicht gibt es da was in der Hinterhand, von dem wir hier noch nichts wissen. Schön wär`s, ich bin nämlich auch long.

      Ansonsten allen Lesern auch von meiner Seite nachträglich noch ein gutes neues Jahr . . .

      Michiko
      Avatar
      schrieb am 03.01.07 15:51:41
      Beitrag Nr. 9 ()
      Antwort auf Beitrag Nr.: 26.656.359 von Michiko am 03.01.07 15:43:22michiko, gebe dir uneingeschränkt Recht. Doch durch den Verlauf der letzten Handelstage scheinen einige mehr zu wissen;)
      Avatar
      schrieb am 03.01.07 15:54:42
      Beitrag Nr. 10 ()
      :lick::lick::lick::lick::lick::lick::lick:
      Avatar
      schrieb am 03.01.07 15:55:47
      Beitrag Nr. 11 ()
      Antwort auf Beitrag Nr.: 26.656.561 von Daxboy5000 am 03.01.07 15:51:41Sag ich ja! ;) ;)

      Ob´s vielleicht was mit STATNOME zu tun hat?
      Avatar
      schrieb am 03.01.07 15:57:52
      Beitrag Nr. 12 ()
      Antwort auf Beitrag Nr.: 26.656.639 von Qork am 03.01.07 15:54:42Qork, sind Deine Charts frei zugänglich oder muss man dafür löhnen?
      Avatar
      schrieb am 03.01.07 15:59:25
      Beitrag Nr. 13 ()
      Antwort auf Beitrag Nr.: 26.656.728 von Michiko am 03.01.07 15:57:52FREI
      http://de.advfn.com/p.php?pid=qkquote&btn=s_ok&s_symbol_sele…
      Avatar
      schrieb am 03.01.07 16:01:57
      Beitrag Nr. 14 ()
      Antwort auf Beitrag Nr.: 26.656.767 von Qork am 03.01.07 15:59:25THANX!
      Avatar
      schrieb am 03.01.07 16:08:25
      Beitrag Nr. 15 ()
      Antwort auf Beitrag Nr.: 26.656.767 von Qork am 03.01.07 15:59:251 $ Cent :lick: jetzt nur noch 10 000% :lick:
      Avatar
      schrieb am 03.01.07 16:09:13
      Beitrag Nr. 16 ()
      Antwort auf Beitrag Nr.: 26.656.982 von miss29 am 03.01.07 16:08:25
      Avatar
      schrieb am 03.01.07 16:15:33
      Beitrag Nr. 17 ()
      vielen dank für die zahlreichen antworten und die ehrlichen aussagen.

      ich denke vor einem einstieg sollte man also eher schauen, dass es länger nach oben geht....luft genug ist ja da...

      so ist das immer bei newcomern....erst haben diese kein geld, finanzieren sich durch/+über optionen und dann knalle es irgednwann und der kurs springt hunderte % nach oben, vorausgesetzt, aus den produkten wird etwas...
      noch mal vielen dank
      svenja
      Avatar
      schrieb am 03.01.07 16:18:29
      Beitrag Nr. 18 ()
      Antwort auf Beitrag Nr.: 26.657.172 von brokersvenja007 am 03.01.07 16:15:33Hier wird wenigstens nicht so gepusht ;)
      Avatar
      schrieb am 03.01.07 16:27:54
      Beitrag Nr. 19 ()
      Antwort auf Beitrag Nr.: 26.657.243 von Qork am 03.01.07 16:18:29Gepusht wird ab 1$, damit wir unsere Gewinne realisieren können :laugh:
      Avatar
      schrieb am 03.01.07 16:40:02
      Beitrag Nr. 20 ()
      Antwort auf Beitrag Nr.: 26.657.459 von miss29 am 03.01.07 16:27:54
      Avatar
      schrieb am 03.01.07 16:46:34
      Beitrag Nr. 21 ()
      Antwort auf Beitrag Nr.: 26.657.752 von Qork am 03.01.07 16:40:02Hoffentlich schliessen wie heute mal nachhaltig über 1



      :kiss::kiss::kiss::kiss::kiss::kiss:
      Avatar
      schrieb am 03.01.07 17:18:07
      Beitrag Nr. 22 ()
      Antwort auf Beitrag Nr.: 26.657.921 von Qork am 03.01.07 16:46:34L2

      Symbol: DNAG

      L2 Summary
      Bid Level #MM's Size Ask Level #MM's Size
      0.0095 3 150 0.0100 2 100
      0.0090 4 200 0.0103 2 100
      0.0081 1 50 0.0104 1 50
      0.0080 1 50 0.0106 1 50
      Avatar
      schrieb am 03.01.07 17:20:55
      Beitrag Nr. 23 ()
      Antwort auf Beitrag Nr.: 26.658.661 von Qork am 03.01.07 17:18:07LEVEL2 Orderbuch

      http://66.201.236.134/export/level2.jsp?symbol=dnag
      Avatar
      schrieb am 03.01.07 17:32:06
      Beitrag Nr. 24 ()
      Antwort auf Beitrag Nr.: 26.657.921 von Qork am 03.01.07 16:46:34Qork, erfahrungsgemäß bröckelt es ab jetzt wieder ab.

      Sollte mich freuen, wenn es diesmal anders wäre.
      Avatar
      schrieb am 03.01.07 17:39:34
      Beitrag Nr. 25 ()
      Antwort auf Beitrag Nr.: 26.659.034 von Michiko am 03.01.07 17:32:06Ich bin erst ca.3 Wochen dabei,mal schauen!!!!!!!!!!!!!

      Wie ich sehe Du schon länger.
      Avatar
      schrieb am 03.01.07 17:46:03
      Beitrag Nr. 26 ()
      Avatar
      schrieb am 03.01.07 19:45:04
      Beitrag Nr. 27 ()
      Antwort auf Beitrag Nr.: 26.659.423 von Qork am 03.01.07 17:46:03Jetzt kommt Volumen:


      Avatar
      schrieb am 03.01.07 22:28:50
      Beitrag Nr. 28 ()
      Antwort auf Beitrag Nr.: 26.659.233 von Qork am 03.01.07 17:39:34Ebenso ca. 3 Wochen!
      Frohes neues noch
      auf ein gutes Jahr!
      Gruß:)
      Avatar
      schrieb am 04.01.07 13:10:25
      Beitrag Nr. 29 ()
      Lassen wir den Subpenny-Bereich heute Nachhaltig hinter uns????????????
      Ich denke dafür braüchten wir noch mehr Volumen,war jedenfalls ein guter Start ins neue Börsenjahr.

      :lick::lick::lick::lick::lick::lick::lick::lick::lick::lick::lick:
      Avatar
      schrieb am 04.01.07 15:13:26
      Beitrag Nr. 30 ()

      Avatar
      schrieb am 04.01.07 16:31:33
      Beitrag Nr. 31 ()
      Antwort auf Beitrag Nr.: 26.673.852 von Qork am 04.01.07 15:13:26Bid Level #MM's Size Ask Level #MM's Size
      0.0100 2 100 0.0103 2 100
      0.0099 2 100 0.0106 1 50
      0.0097 1 50 0.0110 2 100
      0.0094 1 50 0.0120 6 300 :rolleyes:mit mehr Volumen kann da heute hingehen
      Avatar
      schrieb am 05.01.07 12:26:25
      Beitrag Nr. 32 ()
      Hallo

      Kann mir mal einer sagen, warum diese Aktie in Deutschland so wenig gehandelt wird? Hier kommst man ja fast an keine Stücke ran :(

      Gruß

      Laffel
      Avatar
      schrieb am 05.01.07 13:38:52
      Beitrag Nr. 33 ()
      Antwort auf Beitrag Nr.: 26.688.418 von Laffel-2 am 05.01.07 12:26:25Genau deshalb würde ich nur in US Ordern,weil sonst bekommst sie in D nicht mehr los
      Avatar
      schrieb am 05.01.07 13:41:28
      Beitrag Nr. 34 ()
      Antwort auf Beitrag Nr.: 26.690.093 von Qork am 05.01.07 13:38:5229.12.2006 0,007 0,013 0,004 0,005 3.869.162 28.411,00 40
      01.12.2006 0,01 0,01 0,006 0,007 787.000 5.159,00 17
      01.11.2006 0,007 0,01 0,006 0,01 1.462.425 11.284,00 37
      29.09.2006 0,012 0,012 0,006 0,006 1.639.141 16.247,00 45
      01.09.2006 0,012 0,016 0,009 0,01 9.606.290 128.817,00 111
      01.08.2006 0,015 0,015 0,005 0,012 430.500 4.309,00 42
      30.06.2006 0,019 0,025 0,013 0,015 280.750 5.167,00 31
      01.06.2006 0,015 0,021 0,015 0,019 221.750 3.646,00 27
      28.04.2006 0,02 0,02 0,015 0,015 677.000 10.655,00 31
      31.03.2006 0,02 0,03 0,015 0,022 1.163.914 29.415,00 41
      01.03.2006 0,015 0,038 0,015 0,02 723.000 17.106,00 38
      27.01.2006 0,016 0,02 0,014 0,015 327.367 5.552,00 25
      Avatar
      schrieb am 05.01.07 13:51:51
      Beitrag Nr. 35 ()
      Antwort auf Beitrag Nr.: 26.690.093 von Qork am 05.01.07 13:38:52Hat das einen bestimmten Grund?

      Ich kann nicht in US ordern, habe dort keinen Broker, oder geht das auch über Comdirect??
      Avatar
      schrieb am 05.01.07 13:56:33
      Beitrag Nr. 36 ()
      Antwort auf Beitrag Nr.: 26.690.416 von Laffel-2 am 05.01.07 13:51:51Dafür brauchst Du keinen US-Broker,ich bin bei Consors und ich meine Comdirekt handelt auch in US,telefonisch gehts mit Sicherheit
      Avatar
      schrieb am 05.01.07 14:49:28
      Beitrag Nr. 37 ()
      Antwort auf Beitrag Nr.: 26.690.547 von Qork am 05.01.07 13:56:33Ich bin sowohl bei comdirect als auch bei consors.

      Bei beiden geht es sowohl telefonisch als auch online.

      Aber: Bei comdirect geht das Limitieren online nur auf 2 Stellen nach dem Komma, telefonisch geht`s auf 3 Stellen.

      Bei consors geht´s online auf 3 Stellen und telefonisch auf 4.

      Aber Vorsicht bei comdirect: Ich habe im Lauf des letzten Jahres viermal bei comdirect geordert. Und jedesmal habe ich als Allererstes erst mal lächerliche 500 Stück zugeteilt bekommen und dann in einem zweiten oder sogar dritten Durchgang den Rest.
      Das bedeutet, dass ich für die ersten 500 Stück die komplette Ordergebühr von 27,90 Euretten zusätzlich berappen musste!! :mad: Gebühren-Abzocke vom Feinsten!!
      Ich habe mich Ende letzten Jahres schriftlich beschwert, aber bis jetzt noch keine Antwort erhalten.
      Wenn da nicht noch was Entscheidendes kommt, werde ich bei comdirect nichts mehr ordern.
      Avatar
      schrieb am 05.01.07 14:56:21
      Beitrag Nr. 38 ()
      Antwort auf Beitrag Nr.: 26.691.813 von Michiko am 05.01.07 14:49:28Ich gehe doch mal davon aus, sollte sich das Unternehmen etablieren, dann wird auch der Handel in D wieder anziehen.

      Wie seht Ihr hier die Chancen?
      Avatar
      schrieb am 05.01.07 14:56:46
      Beitrag Nr. 39 ()
      Antwort auf Beitrag Nr.: 26.691.813 von Michiko am 05.01.07 14:49:28Bei Consors kannst Du all or None angeben,also 1 Ausführung oder keine was ich meistens mache.
      Avatar
      schrieb am 05.01.07 15:11:28
      Beitrag Nr. 40 ()
      Laffel: Ich würde an Deiner Stelle nicht in Deutschland ordern, auch wenn der "Behaglichkeitsfaktor" darunter leidet. :D
      Du kriegst die Dinger unter Umständen nicht mehr los! Es kam schon vor, dass das ask dreimal so hoch war wie das bid. 0,003 zu 0,009.

      Qork: Ich habe auch bei Consors geordert und in einem Stück den kompletten Auftrag erfüllt bekommen; auch ohne "all or none".
      Nebenbei: Ich habe irgendwo mal gelesen, das "all or none" nicht vor einer Teilausführung schützt. Ist allerdings schon eine Weile her. Vielleicht hat sich das ja zum Positiven geändert.
      Avatar
      schrieb am 05.01.07 15:24:23
      Beitrag Nr. 41 ()
      Ganz interessant, was unser CEO Dick Gabriel so im Jahr verdient:

      DNAPrint Genomics CEO Richard Gabriel was paid $205,000 by the Sarasota-based genetics testing company during 2005. The development-stage company has a market cap of about $4.2 million.

      Quelle: http://www.heraldtribune.com/apps/pbcs.dll/article?AID=/2007…
      Avatar
      schrieb am 08.01.07 12:33:50
      Beitrag Nr. 42 ()
      Am Freitag 1,4 Mio sell buy 140k wie die ganze Woche fast nur Käufe,das lässt auf eine gute Woche hoffen.
      Avatar
      schrieb am 08.01.07 12:50:47
      Beitrag Nr. 43 ()
      Avatar
      schrieb am 08.01.07 13:04:49
      Beitrag Nr. 44 ()
      Antwort auf Beitrag Nr.: 26.766.534 von Qork am 08.01.07 12:50:47Is aber auch nicht gerade der neueste Bericht??
      Avatar
      schrieb am 08.01.07 13:07:41
      Beitrag Nr. 45 ()
      Antwort auf Beitrag Nr.: 26.766.712 von Laffel-2 am 08.01.07 13:04:49Nur mal zur Erinnerung :D
      Avatar
      schrieb am 08.01.07 13:40:04
      Beitrag Nr. 46 ()
      Antwort auf Beitrag Nr.: 26.766.745 von Qork am 08.01.07 13:07:41Haben die eigentlich schon nennenswerte Einnahmen aus ihren Forschungen?
      Avatar
      schrieb am 08.01.07 13:58:39
      Beitrag Nr. 47 ()
      Antwort auf Beitrag Nr.: 26.767.137 von Laffel-2 am 08.01.07 13:40:04http://biz.yahoo.com/e/061113/dnag.ob10qsb.html
      Avatar
      schrieb am 08.01.07 14:18:33
      Beitrag Nr. 48 ()
      Avatar
      schrieb am 08.01.07 14:38:17
      Beitrag Nr. 49 ()
      Antwort auf Beitrag Nr.: 26.767.702 von Laffel-2 am 08.01.07 14:18:33:p:p:p
      Avatar
      schrieb am 08.01.07 15:01:53
      Beitrag Nr. 50 ()
      Looks like a nice uptrend forming.

      Avatar
      schrieb am 08.01.07 15:12:28
      Beitrag Nr. 51 ()


      Avatar
      schrieb am 08.01.07 21:31:13
      Beitrag Nr. 52 ()
      Wer tritt denn da immer auf die Bremse wenn der Kurs mal steigen will..
      Avatar
      schrieb am 09.01.07 15:13:31
      Beitrag Nr. 53 ()
      Avatar
      schrieb am 09.01.07 15:29:57
      Beitrag Nr. 54 ()
      Antwort auf Beitrag Nr.: 26.792.658 von Qork am 09.01.07 15:13:311,200,000 shares already bid .0104 ask .0106
      Avatar
      schrieb am 09.01.07 15:42:48
      Beitrag Nr. 55 ()
      Antwort auf Beitrag Nr.: 26.793.088 von Qork am 09.01.07 15:29:57Wo sind denn die Postings #52 und 53 geblieben :confused:
      Avatar
      schrieb am 09.01.07 15:44:07
      Beitrag Nr. 56 ()
      Antwort auf Beitrag Nr.: 26.793.436 von Michiko am 09.01.07 15:42:48Systemfehler bei WO heute :cry::cry:
      Avatar
      schrieb am 09.01.07 15:50:00
      Beitrag Nr. 57 ()
      Starkes Volumen
      Avatar
      schrieb am 09.01.07 15:58:09
      Beitrag Nr. 58 ()
      Antwort auf Beitrag Nr.: 26.793.638 von Qork am 09.01.07 15:50:00:eek::eek::eek::eek::eek::eek::eek::eek::eek::eek:
      Avatar
      schrieb am 09.01.07 16:17:27
      Beitrag Nr. 59 ()
      Antwort auf Beitrag Nr.: 26.793.875 von Qork am 09.01.07 15:58:09Krass!! Was geht hier?
      Avatar
      schrieb am 09.01.07 16:20:04
      Beitrag Nr. 60 ()
      Antwort auf Beitrag Nr.: 26.794.423 von Laffel-2 am 09.01.07 16:17:27VOLUMEN mit News in der Pipeline :D:D:D:D
      Avatar
      schrieb am 09.01.07 16:24:59
      Beitrag Nr. 61 ()
      Antwort auf Beitrag Nr.: 26.794.495 von Qork am 09.01.07 16:20:04



      Avatar
      schrieb am 09.01.07 16:26:00
      Beitrag Nr. 62 ()
      Warten wir mal ab bis 22 Uhr aber sonst bitte nur Aufwärts
      Avatar
      schrieb am 09.01.07 16:35:39
      Beitrag Nr. 63 ()
      Antwort auf Beitrag Nr.: 26.794.648 von Laffel-2 am 09.01.07 16:26:00Wenn das neue Jahr bei DNAG so weiter macht, wie es angefangen hat . . .
      Avatar
      schrieb am 09.01.07 16:39:30
      Beitrag Nr. 64 ()
      WWWWWWWWEEEEEEEEEEEE UUUUUUUUUUPPPPPPPPPPPPPPPPP
      Avatar
      schrieb am 09.01.07 16:39:32
      Beitrag Nr. 65 ()
      RT 0,125us$?????

      was passiert denn hier?
      trotzdem, mein SK bei 0,11us$

      Grüße
      Svenja
      Avatar
      schrieb am 09.01.07 16:42:56
      Beitrag Nr. 66 ()
      Antwort auf Beitrag Nr.: 26.794.946 von brokersvenja007 am 09.01.07 16:39:32Leider ist da noch ne Null dazwischen. NOCH! :D
      Avatar
      schrieb am 09.01.07 16:46:31
      Beitrag Nr. 67 ()
      Posted by: nuzzi_boy
      In reply to: None Date:1/9/2007 10:44:30 AM
      Post #of 54170

      Email This Article | Print This Article | Reprints [-] Text [+]
      Jan 9 (Reuters) - Private company Amphora Discovery Corp. said on Tuesday that biotech giant Genentech Inc. (DNA.N: Quote, Profile , Research) agreed to buy the drug discovery company's entire program for an unnamed cancer target.

      Under the terms of the agreement, Genentech acquired all of the intellectual property for the program, which consists of a main preclinical drug candidate, among others, Amphora said in a statement.

      Other terms of the deal were not disclosed.

      Amphora has lead candidates in various disease areas like oncology, inflammation, pain as well as metabolic and Central Nervous System disease. (Reporting by Varsha Tickoo in Bangalore)


      Reuters Pictures

      Editors Choice: Best pictures
      from the last 24 hours.
      View Slideshow

      © Reuters 2007. All Rights Reserved
      Avatar
      schrieb am 09.01.07 17:42:26
      Beitrag Nr. 68 ()
      Avatar
      schrieb am 09.01.07 20:45:25
      Beitrag Nr. 69 ()
      :eek: Jetzt will ich aber endlich mal die Rakete starten sehen :laugh::lick::cool:
      Avatar
      schrieb am 09.01.07 22:59:58
      Beitrag Nr. 70 ()
      sieht doch gut aus...
      Avatar
      schrieb am 10.01.07 10:25:00
      Beitrag Nr. 71 ()
      Ob da heute nochmal so ein Sprung nach oben kommt?
      Avatar
      schrieb am 10.01.07 11:11:16
      Beitrag Nr. 72 ()
      Antwort auf Beitrag Nr.: 26.806.716 von Laffel-2 am 10.01.07 10:25:00Scheint sich ja langsam etwas zu tun!

      Genentech moechte eine Biotechfirma kauften ob damit DNAG gemeint sein koennte. Potential haben Sie ja, wenn man bedenkt das sie von 1 Dollar kommen.

      Gruss

      GlobalKonzept
      Avatar
      schrieb am 10.01.07 12:10:18
      Beitrag Nr. 73 ()
      ;););););););););););)
      Avatar
      schrieb am 10.01.07 12:11:59
      Beitrag Nr. 74 ()
      Antwort auf Beitrag Nr.: 26.808.304 von Qork am 10.01.07 12:10:18Das sieht doch nach einer schönem W-Formung aus :D:D:D
      Avatar
      schrieb am 10.01.07 12:17:20
      Beitrag Nr. 75 ()
      Antwort auf Beitrag Nr.: 26.807.395 von GlobalKonzept am 10.01.07 11:11:16Jan 9 (Reuters) - Private company Amphora Discovery Corp. said on Tuesday that biotech giant Genentech Inc. (DNA.N: Quote, Profile , Research) agreed to buy the drug discovery company\'s entire program for an unnamed cancer target.

      Under the terms of the agreement, Genentech acquired all of the intellectual property for the program, which consists of a main preclinical drug candidate, among others, Amphora said in a statement.

      Other terms of the deal were not disclosed.

      Amphora has lead candidates in various disease areas like oncology, inflammation, pain as well as metabolic and Central Nervous System disease. (Reporting by Varsha Tickoo in Bangalore)
      Avatar
      schrieb am 10.01.07 13:31:31
      Beitrag Nr. 76 ()
      Antwort auf Beitrag Nr.: 26.808.407 von Qork am 10.01.07 12:17:20. . . und außerdem kommen sie nicht von einem Dollar her, sondern aus der Gegend ca. 16 Cent.
      Und das auch nur, weil sie davor einen Resplit 1 für 20 gemacht haben, der den Kurs kurzzeitig künstlich verzwanzigfacht hat bevor er dann wieder auf das vorige Level runterging.
      Avatar
      schrieb am 10.01.07 13:44:48
      Beitrag Nr. 77 ()
      Antwort auf Beitrag Nr.: 26.809.473 von Michiko am 10.01.07 13:31:31Weist Du wieviel O/S es vor dem R/S gab??????
      Avatar
      schrieb am 10.01.07 13:53:31
      Beitrag Nr. 78 ()
      :rolleyes::rolleyes::rolleyes::rolleyes::rolleyes::rolleyes:

      Brothers In Arms--DNAPrint has to just bring statnome discovery to Lipitor maker(whoever that is:-)) and state that DNAG will get FDA approval to sell their test, or that company partners with DNAPrint and shares in the statnome revenue...
      With BIG money DNAG's Statnome test could get MAJOR publicity, TV radio... and the drug maker will also make big money!
      I'm liking this company!
      We'll see.....




      stockholder101, as I understand Pfizer paid billions to settle lawsuits against the unknown adverse side problems from their drugs. The DNAG technology could have saved them from this had they discovered it sooner. Now that DNAG has perfected their craft I feel a large company like Pfizer can pay DNAG hundreds of millions for their technology and screen their future patients to prevent future multi-million dollar lawsuits due to the adverse complications from their drugs.
      Avatar
      schrieb am 10.01.07 14:07:47
      Beitrag Nr. 79 ()
      Antwort auf Beitrag Nr.: 26.809.682 von Qork am 10.01.07 13:44:48Qork, ich antworte jetzt mal so wie ich mich erinnere. Ich kann mit der einen oder anderen Zahl etwas daneben liegen, aber die Hauptrichtung stimmt:

      Das a/s (die genehmigten shares) liegt bei etwa 1.5 Milliarden.
      Vor dem Resplit lag das o/s so bei ca. 1,3 oder 1,4 Milliarden, sagen wir der Einfachkeit halber mal 1,4 Milliarden.
      Der Firma gingen also ziemlich bedrohlich die shares aus!

      Nach dem Resplit: Das o/s betrug dann nur noch 70 Millionen, nämlich ein Zwanzigstel von 1,4 Milliarden. Da sich am a/s aber nichts geändert hatte, konnte die Firma von diesem Zeitpunkt an wieder über mehr als 1,4 Milliarden shares verfügen und das hat sie zum Teil auch inzwischen getan!
      So etwas nennt man Dilution; die Altaktionäre wurden nach Strich und Faden beschissen. Aber die Firma hatte vermutlich keine andere Wahl.

      Kleines Detail am Rande: Die eigenen Aktien des Managements waren von dem Resplit natürlich nicht betroffen!

      Gruß Michiko
      Avatar
      schrieb am 10.01.07 14:12:13
      Beitrag Nr. 80 ()
      Antwort auf Beitrag Nr.: 26.810.024 von Michiko am 10.01.07 14:07:47Vielen Dank,
      so weit ich weiss und im letzten Q10 war die O/S 420 Mio
      Avatar
      schrieb am 10.01.07 14:12:26
      Beitrag Nr. 81 ()
      Antwort auf Beitrag Nr.: 26.809.828 von Qork am 10.01.07 13:53:31Ich verfolge die Diskussionen im ihub-Board auch ziemlich gespannt.
      Stockholder101 hat sich ja vom Paulus zum Saulus und dann wieder zum Paulus gewandelt. Will heißen vom Pusher zum Basher und wieder zurück.

      Aber einige der Gedanken dort sind ziemlich interessant; es könnte wirklich sein, dass da etwas am Reifen ist. :rolleyes:
      Avatar
      schrieb am 10.01.07 14:15:08
      Beitrag Nr. 82 ()
      Antwort auf Beitrag Nr.: 26.810.089 von Qork am 10.01.07 14:12:13Wichtig wäre nicht nur das momentane o/s, sondern auch dessen zeitliche Entwicklung!
      Wegen einer Hochrechnung, wann wir mit dem nächsten Resplit rechnen können :cry: :cry:
      Avatar
      schrieb am 10.01.07 14:25:33
      Beitrag Nr. 83 ()
      Antwort auf Beitrag Nr.: 26.810.134 von Michiko am 10.01.07 14:15:0810.05 150 MIO
      03.06 150 MIO
      05.06 346 MIo
      08.06 381 MIO
      10.06 420 MIO
      Avatar
      schrieb am 10.01.07 14:27:15
      Beitrag Nr. 84 ()
      Antwort auf Beitrag Nr.: 26.810.303 von Qork am 10.01.07 14:25:33Also haben wir noch ca.1 Jahr Zeit :D:D:D
      Avatar
      schrieb am 10.01.07 14:32:51
      Beitrag Nr. 85 ()
      Antwort auf Beitrag Nr.: 26.810.024 von Michiko am 10.01.07 14:07:47Kleines Detail am Rande: Die eigenen Aktien des Managements waren von dem Resplit natürlich nicht betroffen!

      Gibst das wirklich,na ja wenigstens kein dummes Managment :laugh::laugh::laugh::laugh:
      Avatar
      schrieb am 10.01.07 15:21:59
      Beitrag Nr. 86 ()


      Avatar
      schrieb am 10.01.07 15:49:04
      Beitrag Nr. 87 ()
      Antwort auf Beitrag Nr.: 26.811.589 von Qork am 10.01.07 15:21:59Der erste Umsatz ist mit 237000 St. zu 0,0125 gemacht worden. Scheint sich auf dem Niveau gut zu halten.

      Gruss

      GlobalKonzept
      Avatar
      schrieb am 10.01.07 16:02:54
      Beitrag Nr. 88 ()
      Antwort auf Beitrag Nr.: 26.812.425 von GlobalKonzept am 10.01.07 15:49:04Jetzt sind wir schon bei 0,0135 mit 2,5 Mill. Umsatz.
      Scheint sich doch etwas zu tun bei DNAG.

      Gruss

      GlobalKonzept
      Avatar
      schrieb am 10.01.07 16:13:09
      Beitrag Nr. 89 ()
      Antwort auf Beitrag Nr.: 26.812.790 von GlobalKonzept am 10.01.07 16:02:54Sieht gut aus!!!!

      SK 14
      Avatar
      schrieb am 10.01.07 16:13:42
      Beitrag Nr. 90 ()
      Avatar
      schrieb am 10.01.07 20:42:06
      Beitrag Nr. 91 ()
      Antwort auf Beitrag Nr.: 26.813.074 von Qork am 10.01.07 16:13:09Ob das nicht etwas zu optimistisch war :D
      Avatar
      schrieb am 10.01.07 20:46:10
      Beitrag Nr. 92 ()
      Antwort auf Beitrag Nr.: 26.818.633 von Laffel-2 am 10.01.07 20:42:06Es würde in das oft erlebte Muster passen, wenn sie jetzt, wo keine News kommen, sich wieder auf ca. 0,007 begeben würden :mad:
      Avatar
      schrieb am 10.01.07 20:47:31
      Beitrag Nr. 93 ()
      Antwort auf Beitrag Nr.: 26.818.633 von Laffel-2 am 10.01.07 20:42:0622.00UHR :D:D:D:D:p
      Avatar
      schrieb am 10.01.07 21:44:02
      Beitrag Nr. 94 ()
      Antwort auf Beitrag Nr.: 26.818.713 von Qork am 10.01.07 20:47:31es wird wohl knapp mit deinem sk :D
      Avatar
      schrieb am 10.01.07 22:05:05
      Beitrag Nr. 95 ()
      Antwort auf Beitrag Nr.: 26.819.815 von Laffel-2 am 10.01.07 21:44:02:D:D:D:D:kiss:
      Avatar
      schrieb am 11.01.07 12:32:28
      Beitrag Nr. 96 ()
      War ja gestern nur ein kleiner Rücksetzer aber das sie Kontinuierlich langsam ist ja auch nicht verkehrt!!!!
      Und das bist jetzt ohne News.

      Avatar
      schrieb am 11.01.07 13:07:21
      Beitrag Nr. 97 ()
      Antwort auf Beitrag Nr.: 26.828.955 von Qork am 11.01.07 12:32:28"War ja gestern nur ein kleiner Rücksetzer"

      Das ist eine gewagte Behauptung! Belege?
      Avatar
      schrieb am 11.01.07 13:09:28
      Beitrag Nr. 98 ()
      Antwort auf Beitrag Nr.: 26.829.685 von Michiko am 11.01.07 13:07:21:confused::confused::confused::confused::confused:
      Avatar
      schrieb am 11.01.07 14:34:39
      Beitrag Nr. 99 ()
      Antwort auf Beitrag Nr.: 26.829.733 von Qork am 11.01.07 13:09:28Was ich meine: Ich bin mir durchaus nicht sicher, dass das nur ein Rücksetzer war und nicht der Beginn eines Downtrends, wie ich ihn nach einem Spike schon oft erlebt habe.
      Avatar
      schrieb am 11.01.07 15:42:33
      Beitrag Nr. 100 ()
      Avatar
      schrieb am 11.01.07 22:01:41
      Beitrag Nr. 101 ()
      Ist die Luft schon wieder raus?
      Avatar
      schrieb am 11.01.07 22:05:02
      Beitrag Nr. 102 ()
      Antwort auf Beitrag Nr.: 26.843.350 von Laffel-2 am 11.01.07 22:01:41Nach momentanem Stand der Dinge wars wieder mal nur heiße Luft ohne Substanz.
      Hab ich schon die ganze Zeit befürchtet. :mad:
      Avatar
      schrieb am 16.01.07 15:46:23
      Beitrag Nr. 103 ()
      Avatar
      schrieb am 16.01.07 21:24:08
      Beitrag Nr. 104 ()
      Naja, dann warten wir halt aufs nächste Zäpfchen :D
      Avatar
      schrieb am 18.01.07 15:55:41
      Beitrag Nr. 105 ()
      Antwort auf Beitrag Nr.: 26.958.357 von Qork am 16.01.07 15:46:23:eek::eek::eek::eek::eek::eek::eek:
      Avatar
      schrieb am 18.01.07 15:58:08
      Beitrag Nr. 106 ()
      Antwort auf Beitrag Nr.: 27.012.627 von Qork am 18.01.07 15:55:41Das Zäpfchen scheint zu wirken :D :D :eek: :eek:
      Avatar
      schrieb am 18.01.07 18:38:21
      Beitrag Nr. 107 ()
      Antwort auf Beitrag Nr.: 27.012.706 von Laffel-2 am 18.01.07 15:58:08:D:D:D:D:D
      Avatar
      schrieb am 18.01.07 20:36:23
      Beitrag Nr. 108 ()
      Na hoffentlich geht da heute Abend noch was
      Avatar
      schrieb am 19.01.07 15:23:44
      Beitrag Nr. 109 ()
      AUF ZUR 15

      Avatar
      schrieb am 22.01.07 21:03:15
      Beitrag Nr. 110 ()
      Antwort auf Beitrag Nr.: 27.033.126 von Qork am 19.01.07 15:23:44Jawoll ja, auf zur 15
      Avatar
      schrieb am 23.01.07 16:21:51
      Beitrag Nr. 111 ()
      Antwort auf Beitrag Nr.: 27.119.308 von Laffel-2 am 22.01.07 21:03:15Fehlt nicht mehr viel :D:D:D
      Avatar
      schrieb am 23.01.07 16:37:54
      Beitrag Nr. 112 ()
      Hmmm ... wie war noch mal mein Einstandspreis vor 6,5 Jahren? :cry:

      So ein paar dausend Prozent müssen hier schon noch kommen, damit ich wieder neutral rauskomme. :rolleyes:

      Aber, man soll ja nie die Hoffung verlieren! :D

      Gruß, g4
      Avatar
      schrieb am 23.01.07 19:19:28
      Beitrag Nr. 113 ()



      Sentiment Stockscore/Rating
      67 Bullish :D
      Avatar
      schrieb am 23.01.07 19:25:50
      Beitrag Nr. 114 ()
      Antwort auf Beitrag Nr.: 27.136.045 von MichiMischtMit am 23.01.07 19:19:28. . . aus dem Grund bin ich auch grad wieder rein! :look:
      Avatar
      schrieb am 23.01.07 22:16:21
      Beitrag Nr. 115 ()
      Wow:eek: am Tageshoch geschlossen!!!!

      Diese Woche noch ne News und up das Ding, bis zum 1€(nur meine Meinung:D)
      Ab 0,0135$ gibt es kein halten mehr:cool:
      http://isht.comdirect.de/charts/big.chart?hist=1y&type=candl…
      Avatar
      schrieb am 23.01.07 22:25:17
      Beitrag Nr. 116 ()
      Antwort auf Beitrag Nr.: 27.136.173 von Michiko am 23.01.07 19:25:50Und weiter gehts :lick:


      DNAPRINT GENOMICS (OTC BB: DNAG.OB) Delayed quote data Edit
      Last Trade: 0.0131 :eek:
      Trade Time: 3:59PM ET
      Change: Up 0.0008 (6.50%)
      Prev Close: 0.0123
      Open: 0.0124
      Bid: 0.0130 x 10000
      Ask: 0.0131 x 5000
      1y Target Est: N/A

      Day's Range: 0.0124 - 0.0131
      52wk Range: N/A
      Volume: 7,610,947
      Avg Vol (3m): N/A
      Market Cap: 5.46M
      P/E (ttm): N/A
      EPS (ttm): -0.041
      Div & Yield: N/A (N/A)


      Avatar
      schrieb am 24.01.07 05:49:14
      Beitrag Nr. 117 ()
      Na das war doch mal ein erfreulicher Tag. Auf zu neun Höhen. 0,05 das würd mir fürs Erste schon mal reichen :D
      Avatar
      schrieb am 24.01.07 11:03:13
      Beitrag Nr. 118 ()
      Wer hat da eigentlich in FFM für 0,007 verkauft?
      Avatar
      schrieb am 24.01.07 15:51:28
      Beitrag Nr. 119 ()
      Avatar
      schrieb am 24.01.07 15:57:31
      Beitrag Nr. 120 ()
      SUUUUPER START 0,015 WIR KOMMEN :D
      Avatar
      schrieb am 24.01.07 16:20:54
      Beitrag Nr. 121 ()
      Antwort auf Beitrag Nr.: 27.153.090 von Laffel-2 am 24.01.07 15:57:31Schöne Buys :D:D:D:D
      Avatar
      schrieb am 24.01.07 17:05:20
      Beitrag Nr. 122 ()
      Dnaprint Genomics Historical stock chart

      Dnaprint Genomics Monthly stock chart

      Dnaprint Genomics Intraday stock chart
      Avatar
      schrieb am 24.01.07 17:23:49
      Beitrag Nr. 123 ()
      Antwort auf Beitrag Nr.: 27.155.039 von Trooper2 am 24.01.07 17:05:20AHA! ;)
      Avatar
      schrieb am 25.01.07 05:47:35
      Beitrag Nr. 124 ()
      Antwort auf Beitrag Nr.: 27.153.769 von Qork am 24.01.07 16:20:54Lag ich ja nicht so weit weg mit meinen 0,015, dann auf ein Neues... Ich erinnere mich Kursziel war ja 0,05 und da fehlt noch etwas... :D

      Gruß

      Laffel
      Avatar
      schrieb am 25.01.07 11:25:32
      Beitrag Nr. 125 ()
      Headline Maker: DNAPrint Announces German Business Partner's Progress in Clinical Trial for BF-200

      Jan 25, 2007 (M2 PRESSWIRE via COMTEX) -- DNAPrint Genomics, Inc. (OTC BB:DNAG) (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
      At the time of writing shares are up 6% over yesterday's close with over 9.7 million in volume. This momentum comes as DNAPrint Genomics, Inc. (OTC BB:DNAG.OB) announced that its German business partner, Biofrontera AG (Frankfurt:B8F.F), in which the Company owns an approximate 10% stake, has completed the enrollment of patients in the first part of its phase IIb/III clinical trial for its lead product, BF-200 ALA, a proposed treatment of actinic keratosis (precancerous and cancerous skin lesions).

      MarketGainer.com has emerged as the most exciting online financial newsletter! For international, small-cap investors who are looking to stay a step ahead of the markets visit MarketGainer.com.

      Initially, clinical results for three different doses of the active ingredient 5-aminolevulinic acid (ALA) and placebo are compared. Following the treatment and 2-month observation of 80 patients enrolled in the first part of the study, independent experts will perform an interim analysis to select the optimal dose of the drug. All 80 patients have already completed the treatment and Biofrontera expects the results of the interim analysis in the first quarter 2007. Subsequently, efficacy and safety of BF-200 ALA will be verified with an additional 160 patients.

      The randomized, placebo-controlled clinical phase IIb/III trial is conducted in 13 centers in Germany. In parallel to the ongoing trial, a second phase III trial is currently prepared with approximately 200 patients to compare BF-200 ALA with a standard therapy. Clinical efficacy of combinations of ALA with nanoemulsions has already been demonstrated for superficial basal cell carcinoma in two earlier phase II trials, where a single treatment eliminated more than 80% of the tumors.

      BF-200 ALA

      Biofrontera's lead product BF-200 ALA combines a nanoemulsion with 5-aminolevulinic acid (ALA). The product is developed for the photodynamic therapy of pre-cancerous skin lesions (actinic keratosis). The ALA nanoemulsion is applied to the skin lesions and, upon irradiation, a chemical reaction is triggered which destroys the affected skin without scar formation.

      Actinic keratosis

      Actinic keratosis or solar keratosis is a precancerous skin lesion. These lesions develop as single, small plaques on the face or bald scalp of a patient and then gradually progress in sun-exposed areas, such as the nose, the forehead, and the cheeks. About 10% of non-treated actinic keratosis progresses to invasive squamous cell carcinoma. Actinic keratosis is the 3rd most common reason for attending a dermatologist. The estimated incidence for actinic keratosis is 5 million new cases per year in Europe.

      About Biofrontera AG

      Biofrontera AG is specialized in the development of pharmaceutical products in the area of dermatology. The company is characterized by a broad, relatively close-to-the-market product portfolio and a solid liquidity. Biofrontera is listed in the regulated market of the Dusseldorf stock exchange and other German stock markets under the symbol B8F and the ISIN number DE0006046113. Visit the website at www.biofrontera.com.
      Avatar
      schrieb am 25.01.07 11:46:41
      Beitrag Nr. 126 ()
      Antwort auf Beitrag Nr.: 27.173.696 von Qork am 25.01.07 11:25:32Oh Himmel hilf, mein Englisch ist sooo schei..., ist das jetzt gut für uns????
      Avatar
      schrieb am 25.01.07 11:56:34
      Beitrag Nr. 127 ()
      Antwort auf Beitrag Nr.: 27.174.156 von Laffel-2 am 25.01.07 11:46:41Ja,auf alle Fälle
      Avatar
      schrieb am 25.01.07 14:48:04
      Beitrag Nr. 128 ()
      hallo ihr lieben....

      ich denke, dass es heute auf über 0,016 us$ gehen kann.
      was ist eure meinung?

      ein ganz wichtiger punkt, endlich schaffen wir es einen kontinuierlichen aufstieg hinzulegen, keine ungesunden tagesanstiege, alles in einem gesunden rahmen, volumen nimmt trotz größerer umsätze auch wieder zu...alle vorzeichen auf grün, auf tahgeshoch geschlossen, rechne mit einer eröffnung von 0,0148us$.

      freue mich sehr auf den heutigen tag.

      endlich scheint dnag bzw. die aufsicht den fushern ihr handwerk gelegt zu haben und die shorties sind raus.

      einem anstieg mit positiven news auf 0,1 us$ steht jetzt nicht, gar nichts mehr im weg.

      liebe grüße und bis später
      eure
      svenja
      Avatar
      schrieb am 25.01.07 15:03:05
      Beitrag Nr. 129 ()
      Antwort auf Beitrag Nr.: 27.177.739 von brokersvenja007 am 25.01.07 14:48:040,1??? WOW Mehr würd ich net brauchen :D
      Avatar
      schrieb am 25.01.07 15:34:56
      Beitrag Nr. 130 ()
      :eek::eek::eek::eek::eek:111111111111155555555555555555:D
      Avatar
      schrieb am 25.01.07 15:56:14
      Beitrag Nr. 131 ()
      Antwort auf Beitrag Nr.: 27.178.829 von Qork am 25.01.07 15:34:560,02 heute?? :eek:
      Avatar
      schrieb am 25.01.07 16:02:56
      Beitrag Nr. 132 ()
      Antwort auf Beitrag Nr.: 27.179.535 von Laffel-2 am 25.01.07 15:56:14Eher 16
      Avatar
      schrieb am 25.01.07 16:07:40
      Beitrag Nr. 133 ()
      Antwort auf Beitrag Nr.: 27.179.749 von Qork am 25.01.07 16:02:56Mein Tipp: 15
      Avatar
      schrieb am 25.01.07 17:03:51
      Beitrag Nr. 134 ()
      lass uns doch lieber einem langsamen anstieg beiwohnen....
      da haben wir doch alle mehr von...
      also, alles zwischen 0,0152 und 0,016 ist gesund...wie schauts mit dem volumen aus?

      da geht bestimmt noch etwas mehr...

      also, hören uns heute nach 22 uhr..
      svenja
      Avatar
      schrieb am 25.01.07 17:28:12
      Beitrag Nr. 135 ()
      na da hat doch mal eben jeamnd 800.000 stücke geordert?!!!
      respekt..immerhin auch nicht wenig >10.000€

      ohne grund: NEIN

      svenja

      RT: 0.0156us$
      Avatar
      schrieb am 25.01.07 17:36:41
      Beitrag Nr. 136 ()
      Avatar
      schrieb am 25.01.07 17:40:26
      Beitrag Nr. 137 ()
      Antwort auf Beitrag Nr.: 27.179.749 von Qork am 25.01.07 16:02:56Moin Qork,
      bin auch dabei.:D:D
      Lassen wir das Teil starten.:cool:
      Avatar
      schrieb am 25.01.07 17:48:15
      Beitrag Nr. 138 ()
      Die Broker in Frankfurt spinnen!!!
      Ein grauenhafter Spreat!:keks::keks::keks::cry:
      Wollen die uns nicht,oder was???
      Ist aber eh gut, kaufen alle eh in Amerika!!
      Also auf die 0,02$

      Prost
      Avatar
      schrieb am 25.01.07 17:50:53
      Beitrag Nr. 139 ()
      :eek: was geht denn jetzt ab??:eek:

      RT 0,0163us$

      wahnsinn, schon wieder 20% gewinn heute...

      Leute wach sein...
      da kommt richtig etwas auf uns zu...das warten scheint sich gelohnt zu haben...bin seit über zwei jahren dabei...

      DNAG hat gute arbeit geleistet, was die news der letzten monate geziegt haben...

      würde mich nicht wundern, wenn wir hier dabei sind, wenn sich ein pennystock zu einem bigplayer entwickelt

      svenja
      Avatar
      schrieb am 25.01.07 17:51:43
      Beitrag Nr. 140 ()
      Antwort auf Beitrag Nr.: 27.182.601 von Eristoff am 25.01.07 17:48:15wieso ? hatte eben 100.000 zu 0,012 nachgekauft

      jetzt scheint das Teil wieder hochgezockt zu werden.
      Avatar
      schrieb am 25.01.07 17:56:04
      Beitrag Nr. 141 ()
      Antwort auf Beitrag Nr.: 27.182.684 von i2fan am 25.01.07 17:51:43Na, dann schau bitte mal auf den Verkaufskurs!!!!!

      0,07€:confused::confused::confused::confused::confused:
      Das meine ich damit.
      Avatar
      schrieb am 25.01.07 17:56:51
      Beitrag Nr. 142 ()
      Antwort auf Beitrag Nr.: 27.182.684 von i2fan am 25.01.07 17:51:43diesmal wird nicht gezockt....diesmal steckt etwas dahinter....

      die shorties sind raus, selbst die börsenaufsicht beobachtet DNAG jetzt genau, nachdem diese ein spielball der zocker waren...es scheint vorbei zu sein und DNAG scheint aufgrund der guten news zu steigen.

      wenn jemand 800.000 aktien auf einmal ordert, dann muss das jemand gewesen sein, der vielleicht etwas weiss....

      was glaubt ihr??

      wo kann der weg noch hingehen??

      alte höchststände??

      svenja
      Avatar
      schrieb am 25.01.07 18:00:56
      Beitrag Nr. 143 ()
      Antwort auf Beitrag Nr.: 27.182.796 von brokersvenja007 am 25.01.07 17:56:51irgendwann kommen auch Gewinnmitnahmen.

      Wenn Kurse steigen, werden auch Zocker angezogen, warum sollten die nicht dabei sein ?
      Sollten keine News kommen, kanns wieder schnell nach unten gehen.
      Avatar
      schrieb am 25.01.07 18:09:42
      Beitrag Nr. 144 ()
      Antwort auf Beitrag Nr.: 27.182.435 von axcol am 25.01.07 17:40:26Servus,freut mich mal wenigstens kein Zocker :rolleyes:
      Avatar
      schrieb am 25.01.07 18:12:41
      Beitrag Nr. 145 ()
      Hoppalla!!

      Na da schau her!! Bid in Frankfurt auf 0,011€.
      Mann braucht nur schimpfen, dann geht's:D
      Avatar
      schrieb am 25.01.07 18:12:53
      Beitrag Nr. 146 ()
      Antwort auf Beitrag Nr.: 27.183.039 von Qork am 25.01.07 18:09:42schaut doch immer besser aus:D

      vielleicht wird´s ja heuer der Knaller;)

      Avatar
      schrieb am 25.01.07 18:13:16
      Beitrag Nr. 147 ()
      Antwort auf Beitrag Nr.: 27.182.796 von brokersvenja007 am 25.01.07 17:56:51Aber nicht bei 800k, solche
      orders mach ich selber das ist kein Insider.

      Bei einer Order ab 5 Mio kannste davon ausgehen
      Avatar
      schrieb am 25.01.07 18:17:35
      Beitrag Nr. 148 ()
      RT 0,017:eek:
      Avatar
      schrieb am 25.01.07 18:23:06
      Beitrag Nr. 149 ()
      Avatar
      schrieb am 25.01.07 18:30:48
      Beitrag Nr. 150 ()
      natürlich gibt es zocker...jedoch waren früher profis /shorties/ bei DNAG am werk...diese sind jetzt nicht mehr so sehr am werk, da dieses spiel durchleuchtet wird, das stand ja groß in der presse...

      zocker sind gut...ein nehmen und geben....

      und´natürlich kann der wert auch heute noch wieder auf 0,0155us$ sinken, aber ein gesunder anstieg sollte doch auch von allen erwünscht sein

      oder????

      svenja
      Avatar
      schrieb am 25.01.07 18:32:21
      Beitrag Nr. 151 ()
      :eek:RT 0,0174us$:eek:
      Avatar
      schrieb am 25.01.07 18:43:06
      Beitrag Nr. 152 ()
      rechne heute mit mehr als 20.000.000 gehandelten stücken in den usa.

      wer hält dagegen??

      svenja
      Avatar
      schrieb am 25.01.07 18:54:28
      Beitrag Nr. 153 ()
      Antwort auf Beitrag Nr.: 27.183.724 von brokersvenja007 am 25.01.07 18:43:06da wird wohl keiner dagegenhalten bei jetzt schon 14 Mio:)

      wenn dieser Anstieg heute gehalten werden kann, wäre es schon
      ganz in Ordnung :cool:
      Avatar
      schrieb am 25.01.07 19:20:35
      Beitrag Nr. 154 ()
      Hat jemand Aktuele R-Time vom Amiland:confused:
      Danke
      Avatar
      schrieb am 25.01.07 19:28:47
      Beitrag Nr. 155 ()
      Antwort auf Beitrag Nr.: 27.184.392 von Eristoff am 25.01.07 19:20:35akt. 0,017


      Avatar
      schrieb am 25.01.07 19:59:52
      Beitrag Nr. 156 ()
      Antwort auf Beitrag Nr.: 27.184.530 von GiovanniTrappertoni am 25.01.07 19:28:47Wow, sogar den Rückgang abgefangen.
      Werden mal sehen was kommt:cool:
      Gute News:kiss::kiss:
      Avatar
      schrieb am 25.01.07 20:08:33
      Beitrag Nr. 157 ()
      Antwort auf Beitrag Nr.: 27.185.145 von Eristoff am 25.01.07 19:59:52YESSS! Das sieht gut aus!

      Ich hatte einen Rückgang auf 0,015 oder so erwartet.

      Mal schaun, wie der Schlusskurs aussieht.
      Avatar
      schrieb am 25.01.07 20:36:49
      Beitrag Nr. 158 ()


      Das sieht doch gut, die Chance auf die 0,02 war da :D

      Aber noch ist ja nicht 22:00 Uhr
      Avatar
      schrieb am 25.01.07 20:41:14
      Beitrag Nr. 159 ()
      Antwort auf Beitrag Nr.: 27.185.811 von Laffel-2 am 25.01.07 20:36:49Bin ma gespannt, ob die 0,016$ jetzt halten??
      Und das ohne irgend einen Hindergrund???
      Bin mal gespannt, wann es was zu lesen gibt!!!
      Avatar
      schrieb am 25.01.07 20:44:26
      Beitrag Nr. 160 ()
      Vielleicht waren es aber auch mal wieder - wie schon so oft - nur die neckischen Spielchen der MMs:
      Den Kurs hochziehen, shares abstoßen und dann wieder runter zum billigen Rückkaufen.
      Und die Depperten sind wieder mal die Kleinanleger.
      Avatar
      schrieb am 25.01.07 20:54:10
      Beitrag Nr. 161 ()
      Antwort auf Beitrag Nr.: 27.185.946 von Michiko am 25.01.07 20:44:26Vielleicht hat es was mit Biofrontera zu tun??
      Forschungsstadium 3-4, ist nicht schlecht!!
      Vielleicht haben sie eine eigene Entwicklung abgeschlossen??
      Was solls???
      Avatar
      schrieb am 25.01.07 20:59:24
      Beitrag Nr. 162 ()
      Ei Du Liebe Sch....

      Mit meinem Bauchgefühl von 0,015 lag ich wohl doch nicht so ganz daneben. :mad:
      Avatar
      schrieb am 25.01.07 21:10:53
      Beitrag Nr. 163 ()
      Antwort auf Beitrag Nr.: 27.186.245 von Michiko am 25.01.07 20:59:24Lass den Kopf nicht rot werden:rolleyes:

      Das ist sogar sehr gesund, solch eine Korrektur.
      Mir wäre es auch lieber, wenn die 0,02$ stehen würde:(
      Avatar
      schrieb am 25.01.07 21:41:26
      Beitrag Nr. 164 ()
      Antwort auf Beitrag Nr.: 27.186.454 von Eristoff am 25.01.07 21:10:53Info: Habe versucht, noch nen Stapel Shares für 0,016 zu erwischen, hab aber nur 5000 Stück bis jetzt gekriegt.
      Sieht so aus, als ob die MMs die Dinger nicht gerne hergeben ;)
      Avatar
      schrieb am 25.01.07 22:18:36
      Beitrag Nr. 165 ()
      Antwort auf Beitrag Nr.: 27.181.562 von brokersvenja007 am 25.01.07 17:03:51na da lag ich doch heute mal recht gut:
      tip zwischen 0,0152-0,016us$

      sk 0,0155us$

      guter gesunder anstieg....

      morgen gehts weiter hoch..........
      vielleicht kommt ja noch eine news..
      gute nacht
      svenja
      Avatar
      schrieb am 25.01.07 22:19:01
      Beitrag Nr. 166 ()
      Antwort auf Beitrag Nr.: 27.187.143 von Michiko am 25.01.07 21:41:26Boah!!!! 0,016$
      Den mutigen gehört die Welt!!!!!
      Bin noch auf der Suche nach einer Investition!!
      Bin derzeit auch in USXP investiert.
      Bin auch an ''Bany'' dran.
      :DNo Risk no Money:D
      Avatar
      schrieb am 25.01.07 22:31:39
      Beitrag Nr. 167 ()
      Antwort auf Beitrag Nr.: 27.187.989 von Eristoff am 25.01.07 22:19:01Sooo mutig bin ich garnicht! :laugh:

      Falls ich mit meinen 0,016 schief liege, habe ich immer noch mein Basis-Invest zu 0,007 bzw. 0,0075.
      Das wird ja hoffentlich so schnell nicht unterboten! :cool:
      Avatar
      schrieb am 26.01.07 14:28:48
      Beitrag Nr. 168 ()
      Hallo Michiko,

      bin einige Tage hinter dem Kurs hinterher gelaufen.Gestern habe
      ich dann für 0,015 und 0,0154 47,5 K eingesackt.
      1 M sind wieder im Depot.Bin nun seit 7 Jahren in DNAG,wird Zeit,
      daß es jetzt aufwärts geht.

      Gruß hvs1
      Avatar
      schrieb am 26.01.07 14:41:00
      Beitrag Nr. 169 ()
      Antwort auf Beitrag Nr.: 27.198.847 von hvs1 am 26.01.07 14:28:48Hallo hvs1, alter Schlachtgenosse! ;)

      Schön, mal wieder was von Dir zu lesen. Eine Million Shares? *Schluck*

      Da bin ich mit meinen 300k ein ziemlich armes Schluckerchen dagegen.
      Ich hab mir vorgenommen, bei DNAG kein gutes Geld mehr dem schlechten hinterher zu werfen. Hab aber trotzdem ein wenig getradet. Erfolg: Einige meiner shares haben Flügel bekommen und sind jetzt weg.
      Das Ding ist wirklich ziemlich unberechenbar.
      Aber: Wir sind ja immer noch voller Hoffnung!

      Gruß Michi

      Übrigens: Meinen alten Thread gibt`s immer noch:
      http://www.wallstreet-online.de/dyn/community/thread.html?th…
      Avatar
      schrieb am 26.01.07 15:16:22
      Beitrag Nr. 170 ()
      Avatar
      schrieb am 26.01.07 15:55:54
      Beitrag Nr. 171 ()
      Antwort auf Beitrag Nr.: 27.199.743 von Qork am 26.01.07 15:16:22:eek: Das sieht nicht gut aus :mad:
      Avatar
      schrieb am 26.01.07 16:00:09
      Beitrag Nr. 172 ()
      Warum der Absturz :confused:
      Avatar
      schrieb am 26.01.07 16:08:49
      Beitrag Nr. 173 ()
      Antwort auf Beitrag Nr.: 27.200.905 von miss29 am 26.01.07 16:00:09warum ? Wochenende, also Gewinnmitnahmen der Zocker ! :D
      Avatar
      schrieb am 29.01.07 17:31:34
      Beitrag Nr. 174 ()
      NEWS :eek:

      http://biz.yahoo.com/iw/070129/0208190.html

      Press Release Source: DNAPrint Genomics, Inc.

      DNAPrint Genomics Continues to Support Police in Mammoth Lakes Murder Case
      Monday January 29, 7:00 am ET

      Chairman Dr. Hector Gomez Helps With Outreach to Spanish-Speaking Community; Company's Methods Are Featured and Explained on News Program

      SARASOTA, FA--(MARKET WIRE)--Jan 29, 2007 -- DNAPrint Genomics, Inc. (OTC BB: DNAG.OB - News) today announced its continuing assistance to the Mammoth Lakes Police Department as Dr. Hector Gomez, DNAPrint Chairman and Chief Medical Officer, joined in a special outreach to the Spanish-speaking community in further attempts to find the killer of a woman whose ethnicity was definitively established by the Company's proprietary DNAWitness™ product.

      ADVERTISEMENT
      Dr. Gomez was featured in a segment of the Univision network program "Aqui Y Ahora" on Thursday, January 18, as he documented the Company's role in the Mammoth Lakes murder case and explained how the ethnicity of the dead woman was identified using DNAPrint's product.

      "I was pleased to take part in this outreach to the Spanish-speaking community as a demonstration of DNAPrint's ongoing commitment to the Mammoth Lakes Police Department and to law enforcement agencies in general," Dr. Gomez said. "DNAPrint's support does not end with the taking of samples and the delivery of a report. The Company will assist law enforcement agencies in any way possible to identify suspects and bring them to justice, and this includes reaching out to the media."

      DNAPrint's role has been crucial from the beginning, according to Sgt. Paul Dostie of the Mammoth Lakes Police Department. "(DNAPrint's involvement) completely turned our investigation around and opened up a new world to us regarding DNA, in that none of the information DNAPrint provided us is available in any government-run crime lab," Sgt. Dostie said.

      Police records in Mammoth Lakes, Calif., note that the remains of a woman were found outside the town in May 2003 and that a preliminary investigation showed that she had been murdered. The corpse was initially identified as the remains of a southeast Asian woman, but Mammoth Lakes police reports show that they used DNAPrint's DNAWitness™ 2.5 test to confirm the identification, and that the test contradicted the original finding. Instead, the test showed that the murder victim was 100% Native American.

      "When I called the Mammoth Lakes PD to discuss the results, I'll never forget the response from Sgt. Dostie," said Dr. Matt Thomas, DNAPrint's Senior Scientist and Lab Manager. "He asked if I was really sure about the result, because the forensic anthropologist identified her as probably Asian. I assured him that our test results were accurate, and suggested other independent testing that could corroborate our findings. In addition, DNAPrint performed a number of blind samples from Native American and Hispanic groups that Sgt. Dostie collected, all of which were properly identified."

      The Mammoth Lakes PD sent hair, bone and mtDNA samples from this case to other experts. The work on these samples has further refined the story in this case and has corroborated DNAPrint's initial results.

      "There is solid evidence that DNAPrint's identification kits, when teamed with the Company's extensive ancestry database, are second to none in forensic accuracy," stated DNAPrint President and Chief Executive Officer Richard J. Gabriel. "Investigative agencies from all over the globe, including the FBI with cases in California and Louisiana, and New Scotland Yard in the case of the Minstead Rapist, have relied on our products and our technical support as they attempt to crack difficult cases. DNAPrint stands ready to assist Sgt. Dostie and his colleagues worldwide in solving these heinous crimes."

      The Native American woman's description and a police artist's reconstruction of her face were immediately distributed to the media. Mammoth Lakes authorities also contacted the Univision television network. Dr. Gomez, whose native language is Spanish, also responded to a call for assistance in explaining the technology.

      "One goal of the investigation was to bring media exposure to the case, specifically Spanish language media," Dr. Thomas said. "A testament to Sgt. Dostie's tenacity in this case has been all the independent and innovative testing he has pulled together, which corroborated our original findings and, better yet, has provided him some very good investigative leads."

      The investigation continues, Dr. Thomas said.

      DNAWitness™ employs patent-pending, database-driven methods to infer elements of physical appearance from crime scene DNA and to allow forensic investigators to "paint" molecular portraits of a suspect. This innovative forensic technology has already been used in some 150 cases, including the arrest and conviction of Derrick Todd Lee for a series of murders in Louisiana and in New Scotland Yard's search for the so-called Minstead Rapist, a serial sex offender who is operating in an area south of London.

      DNAWitness™ determines the percentage of European, East Asian, Native American, and Sub-Saharan African markers in a person's DNA. This ratio for an individual is termed Bio-Geographical Ancestry (BGA), representing general characteristics that can be matched with a searchable database containing information and photographs collected from samples around the world, leading to more accurate determinations of criminal perpetrators.

      Retinome™ 2.0 can be combined with the DNAWitness™ product to determine a person's eye color. The Company's patent-pending technology identifies additional markers covering newly identified and informative regions of the human pigmentation gene OCA2. The Company has also developed a Retinome 2.0 capillary electrophoresis kit, which permits investigators to test Retinome 2.0 in their own laboratories, obviating the need to ship their samples to DNAPrint (though that option is still available).

      DNAPrint also is able to perform tests for mitochondrial and Y DNA trace samples or mixtures. DNAPrint and its wholly owned subsidiary Trace Genetics have the largest volunteer Native American databases of DNA...
      Avatar
      schrieb am 30.01.07 15:40:35
      Beitrag Nr. 175 ()
      Avatar
      schrieb am 30.01.07 15:54:48
      Beitrag Nr. 176 ()
      UPSSS

      Hier der Richtige

      Avatar
      schrieb am 30.01.07 16:43:30
      Beitrag Nr. 177 ()
      Antwort auf Beitrag Nr.: 27.297.527 von Laffel-2 am 30.01.07 15:54:480,015 :eek:
      Avatar
      schrieb am 30.01.07 17:00:50
      Beitrag Nr. 178 ()
      0,0155 :eek:
      Avatar
      schrieb am 30.01.07 18:40:17
      Beitrag Nr. 179 ()
      Antwort auf Beitrag Nr.: 27.299.495 von MichiMischtMit am 30.01.07 17:00:50Hatten wir ja schon mal... Es sollte nun endlich darüber gehen..
      Avatar
      schrieb am 31.01.07 12:11:42
      Beitrag Nr. 180 ()
      der rückgang war vorprogramiert.

      der gestrige Anstieg verspricht einiges, daher bin ich sehr guter dinge bei DNAP(G)...

      bei guten News wird uns das teilchen noch viel freude bereiten...
      liebe grüße
      eure
      svenja
      Avatar
      schrieb am 31.01.07 15:55:18
      Beitrag Nr. 181 ()
      In den ersten sieben Minuten über 1 Mio. Volumen :eek:
      Avatar
      schrieb am 31.01.07 15:56:17
      Beitrag Nr. 182 ()
      Avatar
      schrieb am 31.01.07 17:30:46
      Beitrag Nr. 183 ()
      Biofrontera sieht auch gut aus :eek:





      Avatar
      schrieb am 31.01.07 17:52:44
      Beitrag Nr. 184 ()
      NUR WEITER SOOOOOOOO :D :D
      Avatar
      schrieb am 31.01.07 18:12:41
      Beitrag Nr. 185 ()
      na sieht doch alles sehr sehr vielversprechend aus...
      weiter so DNAG

      svenja
      Avatar
      schrieb am 31.01.07 21:31:54
      Beitrag Nr. 186 ()
      Antwort auf Beitrag Nr.: 27.327.092 von brokersvenja007 am 31.01.07 18:12:41Und morgen die 0,02, das wäre doch mal was :D
      Avatar
      schrieb am 01.02.07 08:49:55
      Beitrag Nr. 187 ()
      Was ist denn das ??? :laugh: :laugh: :laugh:

      18:52:03 0,0170 500 = 8,5 USD
      18:50:25 0,0170 5000
      18:49:44 0,0170 500
      Avatar
      schrieb am 01.02.07 12:54:34
      Beitrag Nr. 188 ()
      Antwort auf Beitrag Nr.: 27.338.587 von Laffel-2 am 01.02.07 08:49:55Laffel-2, das kenne ich ziemlich gut aus leidvoller Erfahrung.

      Den Grund dafür kannst Du im folgenden Thread im Posting #212 nachlesen:

      http://www.wallstreet-online.de/dyn/community/thread.html?th…
      Avatar
      schrieb am 01.02.07 13:38:17
      Beitrag Nr. 189 ()
      Antwort auf Beitrag Nr.: 27.344.702 von Michiko am 01.02.07 12:54:34Das gilt wohl für US-Order?

      Ich habe den fehler gemacht und in Germany gekauft und hier bewegt sich leider nicht viel. Ich hoffe, dass sich das noch ändern wird, wenn wir dann bei 0,05 USD angelangt sind :D
      Avatar
      schrieb am 01.02.07 15:32:06
      Beitrag Nr. 190 ()
      Avatar
      schrieb am 01.02.07 16:20:47
      Beitrag Nr. 191 ()
      Antwort auf Beitrag Nr.: 27.348.072 von Laffel-2 am 01.02.07 15:32:06Na lso doch, wir haben noch ne menge Luft nach oben :D
      Avatar
      schrieb am 01.02.07 16:21:04
      Beitrag Nr. 192 ()
      lso = los
      Avatar
      schrieb am 01.02.07 17:34:59
      Beitrag Nr. 193 ()
      Avatar
      schrieb am 01.02.07 17:51:07
      Beitrag Nr. 194 ()
      Super, mich freut diese langersehnte Aufwärtsbewegung jedoch fehlen noch die entsprechenden Nachrichten.
      Avatar
      schrieb am 01.02.07 21:25:43
      Beitrag Nr. 195 ()
      Antwort auf Beitrag Nr.: 27.351.831 von Konsum-Kind am 01.02.07 17:51:07die news werden kommen, ihr werdet sehen.
      wir sollten uns über den moderaten anstieg freuen.
      die vorzeichen sind grün und der chart sieht immer besser aus...

      eure
      svenja
      Avatar
      schrieb am 02.02.07 08:56:16
      Beitrag Nr. 196 ()
      Guten Morgen!

      Habe mich eben mal hingesetzt und meinen Einstandskurs ausgerechnet. Die ersten Shares habe ich um 1999/2000 herum gekauft. Hatte zuletzt irgendwann mal 400.000 Stück, nach dem R/S sind die dann auf 20.000 Stück geschrumpft - zum Schnäppchenpreis von 2,20 € / Stück! :cry::rolleyes::eek:

      Geil, was? Also, ich brauche jetzt einen Anstieg um 17.000 % - dann bin ich wieder +/- Null!

      Ich könnte aber auch noch mal einen Tausi in die Hand nehmen, dann könnte ichmeinen Einstiegskurs auf ca. 0,60 € reduzieren und bräuchte folglich nur noch einen Anstieg um ca. 4.500 % um auf +/- Null zu kommen .... :rolleyes:

      Was würdet Ihr machen?

      Gruß, g4
      Avatar
      schrieb am 02.02.07 09:24:29
      Beitrag Nr. 197 ()
      verbilligen....
      es wird sich lohnen.

      aber du m,ußt ja nicht gleich übertreiben.

      viel erfolg
      svenja

      ps: heute sehen wir die 0,018us$:eek:
      Avatar
      schrieb am 02.02.07 10:01:34
      Beitrag Nr. 198 ()
      Antwort auf Beitrag Nr.: 27.362.199 von brokersvenja007 am 02.02.07 09:24:29Das wollen wir doch mal schwer hoffen :D :D

      Der gestrige Kursverlauf war auf jeden Fall sehr angenehm :D
      Avatar
      schrieb am 02.02.07 10:03:36
      Beitrag Nr. 199 ()
      Antwort auf Beitrag Nr.: 27.361.733 von ge4teilter am 02.02.07 08:56:16Also ich habe irgendwo gelesen Kursziel 0,05

      Es würde sich also auf jeden Fall lohnen zu verbilligen.

      Aber 2,20 zu erreichen :eek: ..... Die Krönung wäre es alle mal :D
      Avatar
      schrieb am 02.02.07 11:55:37
      Beitrag Nr. 200 ()
      Antwort auf Beitrag Nr.: 27.361.733 von ge4teilter am 02.02.07 08:56:16g4, für mich habe ich die Entscheidung ja schon vor einiger Zeit getroffen:

      Ich habe wieder rückgekauft, also hoffe ich auf einen Erfolg!

      Gruß Michi
      Avatar
      schrieb am 05.02.07 15:36:54
      Beitrag Nr. 201 ()


      Schon mal ein guter Start :D
      Avatar
      schrieb am 05.02.07 18:24:52
      Beitrag Nr. 202 ()
      Antwort auf Beitrag Nr.: 27.361.733 von ge4teilter am 02.02.07 08:56:16Also G4, ohne beleidigend zu werden würde ich dir raten dich entweder aktiver mit deinen Werten zu beschäftigen, Limits setzen ernen oder mit dem Traden aufhören!!! Wieso bist du nie rausgegangen? Handelst du nach dem Motto die Hoffnung stirbt zuletzt? Ich hoffe mal du hast seit 2000 einiges dazugelernt
      Avatar
      schrieb am 05.02.07 21:17:52
      Beitrag Nr. 203 ()
      G4,

      Michiko und ich sind wohl die Longshareholder aus 2000.Ich habe aufgestockt auf 1M,ohne zu verkaufen,Michiko hat teilweise verkauft,was ich hätte auch tun sollen,aber nicht getan habe.
      Sollte die 0,0175 noch diese Woche halten, stocke ich nochmals auf.
      Wir sind doch von dieser Firma bzw. von deren Produkten überzeugt,
      sonst hätten wir uns schon längst davon verabschiedet.
      Wir haben zwar erhebliche Verluste eingefahren,aber es ja noch nicht aller Tage "Abend".

      Grüß Dich
      hvs1
      Avatar
      schrieb am 06.02.07 14:20:54
      Beitrag Nr. 204 ()
      DNAPrint Genomics

      CONTACT

      Corporate Headquarters
      We have moved, our new address is:
      1621 West University Parkway
      Sarasota, FL 34243





      Avatar
      schrieb am 06.02.07 14:50:47
      Beitrag Nr. 205 ()
      Antwort auf Beitrag Nr.: 27.462.023 von MichiMischtMit am 06.02.07 14:20:54Ist das da, wo jetzt das schwarze Loch ist?













      :D :D
      Avatar
      schrieb am 06.02.07 14:51:28
      Beitrag Nr. 206 ()
      Ob wir heute die 0,018 sehen?!
      Avatar
      schrieb am 06.02.07 16:15:30
      Beitrag Nr. 207 ()
      Avatar
      schrieb am 06.02.07 16:21:47
      Beitrag Nr. 208 ()
      0,0173 das ist aber die falsche Richtung :mad:
      Avatar
      schrieb am 06.02.07 16:24:17
      Beitrag Nr. 209 ()
      Antwort auf Beitrag Nr.: 27.464.857 von MichiMischtMit am 06.02.07 16:21:47Ja leider :(
      Avatar
      schrieb am 06.02.07 16:47:36
      Beitrag Nr. 210 ()
      Antwort auf Beitrag Nr.: 27.464.935 von Laffel-2 am 06.02.07 16:24:170,017 Fallen wir jetzt in das schwarze Loch :cry:
      Avatar
      schrieb am 06.02.07 17:06:15
      Beitrag Nr. 211 ()
      Habe meine mal ins trockene gebracht
      Avatar
      schrieb am 06.02.07 17:08:03
      Beitrag Nr. 212 ()
      Die Käufer der letzten Wochen sind wohl aufgrund der Gerüchte eingestiegen (buy on rumors).

      Jetzt, wo (wieder mal) nix kommt, wird halt achselzuckend wieder verkauft. Mit Tuesday = Newsday war es wohl nichts!

      Könnte wieder in den Subpenny-Bereich sinken :(
      Avatar
      schrieb am 06.02.07 17:16:52
      Beitrag Nr. 213 ()
      Antwort auf Beitrag Nr.: 27.466.227 von Michiko am 06.02.07 17:08:03Du schreibst könnte!!!
      Muss aber nicht!
      Ist immer mal schön Gewinne mit zu nehmen.:D
      Versuche es wieder mal mit Swiss fe!!
      Hat schon 2x geklappt:cool:
      Halte ein Auge auf euch;)
      Avatar
      schrieb am 06.02.07 17:19:49
      Beitrag Nr. 214 ()
      Avatar
      schrieb am 07.02.07 05:43:04
      Beitrag Nr. 215 ()
      Antwort auf Beitrag Nr.: 27.466.555 von MichiMischtMit am 06.02.07 17:19:49Man könnte auch sagen, gerade nochmal die Kurve bekommen... Bin mal gespannt wie es heute weiter geht. Schade das hier keine Nachrichten mehr nachgelegt werden..
      Avatar
      schrieb am 07.02.07 12:49:22
      Beitrag Nr. 216 ()
      Hier noch eine Meldung vom 06.02.2007


      DNAPrint Genomics AncestryByDNA(TM) Product Helps New York City Seventh Graders Learn About Their Pasts
      Students Surprised by Results; Project Draws Media Attention
      DNAPrint Genomics, Inc. (OTCBB: DNAG), today announced the successful completion of an ancestry project involving five classes at Middle School 223, The Laboratory School of Finance and Technology in The Bronx, a New York City borough, that employed the Company's proprietary AncestryByDNA(TM) product and which rendered results that surprised some of the students and drew media attention.

      The project was the brainchild of Eric Lincoln, a teacher at the Bronx school. The project involved the taking of swab samples from 11 students (nine Hispanic and two African-American) who were selected on the basis of written essays, and a sample from Mr. Lincoln, a Caucasian. DNAPrint Genomics donated 12 AncestryByDNA(TM) kits and processing fees to the project.

      The results surprised some students, who were profiled in stories that ran in The New York Daily News and on New York 1, the local cable news channel.

      "I didn't know I had European family," said Sheila Guerrios, age 12, who self-identified as Hispanic but was shown to be 63% European, 25% sub-Saharan African, and 12% East Asian. "That's weird to me." She also said her family was confused by the results, especially the East Asian heritage, because both parents were from Puerto Rico.

      Rossay Gomez, age 12, had a similar reaction. Her DNA tested 69% European and 31% sub-Saharan African. "I thought I was going to be Native American," she said.

      The study's two African American students were also surprised to find they had 19% and 23% European DNA, respectively, according to Mr. Lincoln. Results from DNAPrint's extensive, proprietary database often show African-Americans to be 20% European and 5% Native American.

      "I can't think of a more interesting way to make real the interaction of people in the Americas 500 years ago than with our own ancestry as the evidence," stated Eric Lincoln, Seventh Grade Leader and Social Studies Teacher at Middle School 223. "This project has truly brought history alive for my students."

      "During the summer of 2006, the teacher, Eric Lincoln, wrote to the Company, asking whether we were willing to donate kits as part of a student history project," said DNAPrint President and Chief Executive Officer Richard J. Gabriel. "Apparently, he had seen AncestryByDNA(TM) demonstrated on 'African American Lives,' the Public Broadcasting Program, and he wanted to integrate personal DNA results into the students' American history curriculum. We immediately agreed, realizing that this would be an excellent chance for students to explore their ancestry and give them heretofore-unknown insights into their rich backgrounds. We also knew that this could motivate other students -- and their parents -- to learn more about their own DNA genetic histories and to learn more about themselves as humans."

      Media coverage of the project is available from the New York Daily News at http://www.nydailynews.com/boroughs/story/489193p-411987c.ht… and New York 1 at http://www.ny1.com/ny1/content/index.jsp?&aid=65819&search_r…

      About AncestryByDNA(TM)

      AncestryByDNA(TM), the flagship product of DNAPrint's Genealogy group, is an affordable way for the people to discover their hereditary profiles. AncestryByDNA will determine genetic heritage among the four anthropological groups: Native American; East Asian; Sub-Saharan African (areas south of the Sahara Desert); Indo-European (Europe, Middle East, North Africa, Western Asia).

      These groups are named using modern-day terms but represent anthropological lineages that extend back in time tens of thousands of years. For example, the term "European" is meant to describe a common ancestry held by peoples from continental Europe, the Middle East, Eurasia, Central Asia and South Asia -- sometimes referred to as "Caucasoids." EuroDNA is a more advanced analysis tool that allows our clients of Indo-European heritage to more thoroughly understand their ancestry. The tests are simple and painless, and an Ancestry Certification Analysis is shipped within a matter of weeks. For more information, visit http://www.ancestrybydna.com/welcome/.

      About DNAPrint Genomics, Inc.

      DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.



      Source: Market Wire (February 6, 2007 - 7:02 AM EST)

      News by QuoteMedia
      www.quotemedia.com
      Avatar
      schrieb am 07.02.07 13:55:58
      Beitrag Nr. 217 ()
      ...Media coverage of the project is available from the New York Daily News at

      http://www.nydailynews.com/boroughs/story/489193p-411987c.ht…...

      Der Traffic Rank ist spitze :eek:
      Davon können wir bei Gameznflix nur träumen :laugh:

      Avatar
      schrieb am 07.02.07 20:43:49
      Beitrag Nr. 218 ()
      0,0155 :look:
      Avatar
      schrieb am 07.02.07 20:56:00
      Beitrag Nr. 219 ()
      Avatar
      schrieb am 08.02.07 16:26:04
      Beitrag Nr. 220 ()
      Mein Stopp-Loss bei 0,014 ist bald erreicht :rolleyes:
      Avatar
      schrieb am 08.02.07 17:39:31
      Beitrag Nr. 221 ()
      Antwort auf Beitrag Nr.: 27.515.182 von MichiMischtMit am 08.02.07 16:26:04Wirst Du dann alles schütten, oder behältst Du noch ein paar Dinger?
      Avatar
      schrieb am 08.02.07 17:59:59
      Beitrag Nr. 222 ()
      Antwort auf Beitrag Nr.: 27.517.870 von Michiko am 08.02.07 17:39:31Ja alle, sind aber nur 99.000 Stück ;)
      Avatar
      schrieb am 08.02.07 18:03:36
      Beitrag Nr. 223 ()
      Antwort auf Beitrag Nr.: 27.517.870 von Michiko am 08.02.07 17:39:31DNAPRINT GENOMICS (OTC BB: DNAG.OB) Delayed quote data Edit
      Last Trade: 0.0145
      Trade Time: 10:46AM ET
      Change: Down 0.0005 (3.33%)
      Prev Close: 0.015
      Open: 0.0145
      Bid: 0.0141 x 5000 :eek::eek::eek: Und das schon eine ganze Weile :mad:
      Ask: 0.0150 x 10000
      1y Target Est: N/A
      Avatar
      schrieb am 08.02.07 18:22:15
      Beitrag Nr. 224 ()
      Wer verkauft denn da 100 Stück :mad::laugh:
      Avatar
      schrieb am 08.02.07 18:32:55
      Beitrag Nr. 225 ()
      0,0145 :eek:

      VIelleicht gibt es ja doch noch Hoffnung :look:
      Avatar
      schrieb am 08.02.07 18:43:31
      Beitrag Nr. 226 ()
      Avatar
      schrieb am 08.02.07 18:48:57
      Beitrag Nr. 227 ()
      0,015 :)
      Avatar
      schrieb am 08.02.07 19:01:18
      Beitrag Nr. 228 ()
      Antwort auf Beitrag Nr.: 27.520.473 von MichiMischtMit am 08.02.07 18:48:57Jetzt kannste getrost noch 1000 shares nachkaufen.

      Dann biste 6-stellig! :laugh:
      Avatar
      schrieb am 08.02.07 19:30:31
      Beitrag Nr. 229 ()
      Antwort auf Beitrag Nr.: 27.521.077 von Michiko am 08.02.07 19:01:18Nix, kein Cash mehr :(


      Aber was sehe ich gerade,
      Seit 18:30 6 Kauforders hintereinander :eek:
      Das sieht gut aus :look:
      Avatar
      schrieb am 08.02.07 19:32:53
      Beitrag Nr. 230 ()
      Antwort auf Beitrag Nr.: 27.522.402 von MichiMischtMit am 08.02.07 19:30:31Jetzt 7 hintereinander :eek:
      Avatar
      schrieb am 08.02.07 19:38:10
      Beitrag Nr. 231 ()
      Antwort auf Beitrag Nr.: 27.522.525 von MichiMischtMit am 08.02.07 19:32:538 :eek:
      Avatar
      schrieb am 08.02.07 19:39:14
      Beitrag Nr. 232 ()
      Avatar
      schrieb am 08.02.07 19:45:49
      Beitrag Nr. 233 ()
      0,0155 :eek:
      Avatar
      schrieb am 08.02.07 20:29:55
      Beitrag Nr. 234 ()
      Antwort auf Beitrag Nr.: 27.523.168 von MichiMischtMit am 08.02.07 19:45:49Sieht doch wieder gut aus :D

      Auf zu neuen Höhen
      Avatar
      schrieb am 08.02.07 22:16:28
      Beitrag Nr. 235 ()
      Antwort auf Beitrag Nr.: 27.525.144 von Laffel-2 am 08.02.07 20:29:55Ich bin jedenfalls HAPPY das die 0,0141 gehalten hat

      Avatar
      schrieb am 09.02.07 12:49:19
      Beitrag Nr. 236 ()
      Antwort auf Beitrag Nr.: 27.529.478 von MichiMischtMit am 08.02.07 22:16:28SL also nicht ausgelöst :D

      Und jetzt auf zu 0,02... :D
      Avatar
      schrieb am 09.02.07 16:15:27
      Beitrag Nr. 237 ()
      0,016 :cool:
      Avatar
      schrieb am 09.02.07 16:20:14
      Beitrag Nr. 238 ()
      Da hat doch glatt einer 400.000 Stück gekauft :eek:
      Avatar
      schrieb am 09.02.07 17:07:00
      Beitrag Nr. 239 ()
      NEWS

      http://biz.yahoo.com/iw/070209/0213457.html


      ...Press Release Source: DNAPrint Genomics, Inc.

      DNAPrint(R) Genomics Senior Scientist to Address Second Annual Conference on Crimes Against Women
      Friday February 9, 7:00 am ET

      SARASOTA, FL--(MARKET WIRE)--Feb 9, 2007 -- DNAPrint® Genomics, Inc. (OTC BB: DNAG.OB - News) today announced that DNAPrint® Senior Scientist Matthew Thomas, Ph.D., will take part in a press conference preceding the Second Annual Conference on Crimes Against Women that will take place on Feb. 12, 2007 at 9:30 a.m. Central time, at the Hilton Dallas Lincoln Centre in Dallas, Tex. Dr. Thomas will also take part in the conference itself, which is scheduled for Feb. 12-14.

      ADVERTISEMENT
      click here
      "We are pleased that Dr. Thomas has been chosen to take part in this press conference," stated DNAPrint® President and Chief Executive Officer Richard Gabriel. "Our involvement with law enforcement has shown that our DNAWitness™ with Retinome™ 2.0 products, and now the use of DNA profiling and storage for future purposes, can be beneficial in prosecuting crimes against women and can prevent certain cases from going cold."

      Mr. Gabriel continued, "The National Victim Center and Crime Victim Research and Treatment Center report that there are 683,000 rapes occurring every year, or 1.3 per minute, yet our experience is that there are relatively few arrests being made simply because law enforcement officials are limited by the amount of money that can be spent on DNA testing. Four north Texas rape victims came forward last year and asked for more DNA testing in order to find and convict their rapists. We agree, and we are going to join the fight to get more federal funding for this purpose. This press conference will provide Dr. Thomas with an opportunity to start that process, and to explain to the authorities in Dallas and to the press how the Company's DNA products can provide them with the tools essential to prosecute and convict those who perpetrate these crimes. Dr. Thomas will also call for more DNA testing by the police while at the same time rallying support for full funding of the annual grant for DNA testing that is currently before Congress."

      "We see this press conference as an important opportunity to demonstrate the Company's considerable expertise in DNA testing to law enforcement officials and the general public in the Dallas-Fort Worth market, which is the fifth largest metropolitan area in the United States, and to show them how DNAPrint®'s proprietary DNAWitness™ products have been used in other cases," stated Dr, Thomas. "For example, DNAWintess™ produced evidence that was essential in identifying the correct suspect, Derrick Todd Lee, in the South Louisiana Serial Killer case in 2003. DNAWintess™ products have also played vital roles in the Mammoth Lakes, Calif., murder case and Operation Minstead, which is being conducted by New Scotland Yard in Great Britain. In all of these cases, DNAWitness™ and DNAPrint®'s continuing technical support have kept the trails from going cold and have assisted in guiding the authorities in the right direction. Nonetheless, an essential part of this process is adequate federal funding for DNA testing, which DNAPrint® supports"

      The Second Annual Conference on Crimes Against Women is sponsored by Genesis Women's Shelter of Dallas and the Dallas Police Department, and will focus on the victimization of women and improving the response time of the criminal justice system regarding crimes against them. Conference topics include family violence in military families, federal domestic violence laws, cyber stalking, cold case homicide, domestic violence in a digital age and criminal profiling.

      Other scheduled speakers include: Anita Woolridge, a woman abducted and held captive for seven days by an acquaintance; David Kunkle, Chief of Police, Dallas Police Department; Jan Langbein, Genesis Women's Shelter executive director; Cindy Dyer, chief prosecutor of the Dallas County District Attorney's Office Family Violence Division; Blais Mikulewicz, Assistant Special Agent in Charge of the Dallas Division of FBI Criminal Investigative Squad...
      Avatar
      schrieb am 09.02.07 19:27:37
      Beitrag Nr. 240 ()
      :eek::eek::eek:
      Avatar
      schrieb am 11.02.07 23:24:59
      Beitrag Nr. 241 ()
      Habe mir mal Medigene angeschaut und da habe ich das entdeckt :eek:


      http://www.biofrontera.com/cms/index.php?id=5&L=1
      -> BF-200 ALA = aktinische Keratose + Kondylom (Genitalwarzen)

      http://www.medigene.de/deutsch/projekte.php?allow=true
      -> Polyphenon® E-Salbe = aktinische Keratose + Kondylom (Genitalwarzen)
      Avatar
      schrieb am 11.02.07 23:25:55
      Beitrag Nr. 242 ()
      Avatar
      schrieb am 12.02.07 15:36:09
      Beitrag Nr. 243 ()
      :eek: 9:03:28 ASK 0,0175 :cool:
      Avatar
      schrieb am 12.02.07 16:38:40
      Beitrag Nr. 244 ()
      Wieso kauft da heute keiner DNAG?

      hvs1
      Avatar
      schrieb am 12.02.07 16:38:47
      Beitrag Nr. 245 ()
      Noch will keiner verkaufen :eek:

      14 Kauforders hintereinander

      Buy Vol. 257.000
      Sell Vol. 0 :D


      15 Min. verzögert !
      Avatar
      schrieb am 12.02.07 16:41:54
      Beitrag Nr. 246 ()
      Antwort auf Beitrag Nr.: 27.662.837 von hvs1 am 12.02.07 16:38:40Die Frage muss lauten: Warum steigt der Kurs nicht :rolleyes:

      TROTZ 16 Kauforders hintereinander :mad:
      Avatar
      schrieb am 12.02.07 18:11:34
      Beitrag Nr. 247 ()
      Bei ONYX PHARM INC geht es ganz schön zur Sache :laugh:


      ONYX PHARM INC (NasdaqGM: ONXX) Delayed quote data Edit
      Last Trade: 22.32
      Trade Time: 11:42AM ET
      Change: Up 10.06 (82.06%) :eek::eek::eek:
      Prev Close: 12.26
      Open: 19.67
      Bid: 22.27 x 100
      Ask: 22.32 x 300
      1y Target Est: 15.67

      Day's Range: 17.95 - 22.43
      52wk Range: 10.38 - 29.10
      Volume: 28,756,673 :eek::eek::eek: = ca. 600.000.000 $ :eek: in Worten SECHSHUNDERT MILLIONEN DOLLAR :eek:
      Avg Vol (3m): 1,683,530
      Market Cap: 974.76M
      P/E (ttm): N/A
      EPS (ttm): -2.72
      Div & Yield: N/A (N/A)
      Avatar
      schrieb am 12.02.07 21:54:40
      Beitrag Nr. 248 ()
      Antwort auf Beitrag Nr.: 27.664.976 von MichiMischtMit am 12.02.07 18:11:34ONYX PHARM INC (NasdaqGM: ONXX) Delayed quote data Edit
      Last Trade: 24.57
      Trade Time: 3:30PM ET
      Change: Up 12.31 (100.41%) :eek::eek::eek:
      Prev Close: 12.26
      Open: 19.67
      Bid: 24.55 x 200
      Ask: 24.59 x 600
      1y Target Est: 15.67

      Day's Range: 17.95 - 25.20
      52wk Range: 10.38 - 29.10
      Volume: 52,776,754 :eek: ca. 1.000.000.000 $ :eek: EINE Milliarde DOLLAR :eek::eek::eek:
      Avg Vol (3m): 1,683,530
      Market Cap: 1.07B
      P/E (ttm): N/A
      EPS (ttm): -2.72
      Div & Yield: N/A (N/A)
      Avatar
      schrieb am 13.02.07 18:36:02
      Beitrag Nr. 249 ()
      NEWS

      http://biz.yahoo.com/iw/070213/0214661.html

      ...Press Release Source: DNAPrint Genomics, Inc.

      DNAPrint(TM) Genomics and Code Amber(R) Form Partnership to Offer Storage of DNA Sequencing on Amber Stick(TM)
      Tuesday February 13, 7:00 am ET

      DNAPrint Also Becomes Sponsor of Code Amber Ticker

      SARASOTA, FL and MANDEVILLE, LA--(MARKET WIRE)--Feb 13, 2007 -- DNAPrint(TM) Genomics, Inc. (OTC BB: DNAG.OB - News) and Code Amber® (www.codeamber.org) today announced a partnership under which consumers would be offered the ability to store a child's DNA sequence on a memory stick for instant accessibility and, at the same time, DNAPrint has become the sponsor of the Code Amber Ticker, a JavaScript news feed ticker that displays active Amber Alerts on an organization's web pages.

      In cooperation with Amber Stick(TM) (http://codeamber.org/idkits.html?front), the only child identification system endorsed by Code Amber, DNA sequencing from DNAPrint(TM) will be stored on a flash memory device, along with photos and descriptions of the child.

      ADVERTISEMENT
      click here
      Code Amber is the most recognized distributor of Amber Alerts on the Internet. With its powerful reach to more than 300,000 web sites and PCs displaying the Code Amber Ticker, millions are alerted when a child is missing or in imminent danger.

      "When children are unintentionally separated from their parents by being lost, abducted or the victim of a disaster, time is critical," said Bryant Harper, President of Code Amber. "With all the identifying information stored safely and accurately in one place, parents can assist law enforcement in the crucial first moments of a reported disappearance. We are proud to have DNAPrint as our sponsor and to offer their dynamic technology to everyone."

      DNAPrint(TM) is a trusted name with law enforcement agencies. They have offered support to international, federal and local authorities with its DNAWitness(TM) and AncestrybyDNA(TM) products, including federal cases in California and Louisiana, with local police in the Mammoth Lakes (Calif.) Murder Case, and with New Scotland Yard in the United Kingdom in the case of the so-called Minstead Rapist.

      "With our close association with the law enforcement community, we have long known that our products were needed in the public sector," stated DNAPrint(TM) CEO and President Richard J. Gabriel. "DNA can be used for more than just identifying suspects, and can be extremely useful in tracking and identifying children after they have gone missing."

      Mr. Gabriel continued, "We undertook this sponsorship to provide support for Code Amber. We also see the potential to support the marketing and sales efforts surrounding our consumer products, specifically the Company's proprietary DNA sequencing and storage products. Code Amber is one of many channels that DNAPrint uses to encourage parents to test and store their children's DNA for purposes of identifying certain gene markers that would indicate sensitivity to certain treatments for various diseases, such as an allergic reaction to penicillin, and Amber Stick is uniquely suited to this purpose in addition to being an aid to finding children when they go missing. We hope that parents everywhere will give serious consideration to availing the services available to them with Amber Stick, and we look forward to partnering with Code Amber in the sponsorship of the Code Amber Ticker."

      About Code Amber

      Based in Mandeville, La., Code Amber is the most recognized distributor of Amber Alerts on the Internet, reaching over 330,000 web sites and personal computers. A leader in the field of child advocacy, Code Amber offers a range of products and services to law enforcement, media, corporations and the public dealing with Amber Alert notification, child safety and information storage. Code Amber's signature Java Script Amber Alert Ticker and XML feed are used throughout North America. For more information, visit www.codeamber.org...
      Avatar
      schrieb am 13.02.07 19:52:49
      Beitrag Nr. 250 ()
      Antwort auf Beitrag Nr.: 27.687.412 von MichiMischtMit am 13.02.07 18:36:02Little Caesars Pizza

      http://littlecaesars.com/

      Ganz unten ist das Code Amber Laufband.

      Da steht ...Code Amber is Sponsored by DNA Print Genomics... :eek:
      Avatar
      schrieb am 13.02.07 20:29:55
      Beitrag Nr. 251 ()
      Naja, die News sind ja auch nicht gerade der Renner... so wie der Kurs :(
      Avatar
      schrieb am 13.02.07 20:54:49
      Beitrag Nr. 252 ()
      Antwort auf Beitrag Nr.: 27.690.017 von Laffel-2 am 13.02.07 20:29:55Allerdings!

      Das alte Lied, das alte Leid!

      Ob das dieses Jahr besser wird? :(
      Avatar
      schrieb am 13.02.07 21:04:14
      Beitrag Nr. 253 ()
      Avatar
      schrieb am 14.02.07 13:42:20
      Beitrag Nr. 254 ()
      Peter Heinrich von Medigene in Bloomberg TV Chefsache :eek:

      Redet auch über aktinische Keratose + Kondylom (Genitalwarzen) :laugh:
      Avatar
      schrieb am 14.02.07 14:32:19
      Beitrag Nr. 255 ()
      http://de.wikipedia.org/wiki/Erythropoetin

      # Unter der Kennung „PT-401“ arbeitet das in Florida ansässige Unternehmen DNAPrint Genomics :eek: in gegenwärtig vorklinischen Studien an einem EPO-Dimer-Präparat, das eine deutlich höhere Affinität zum EPO-Rezeptor haben soll als das native EPO.
      Avatar
      schrieb am 14.02.07 14:53:59
      Beitrag Nr. 256 ()
      Antwort auf Beitrag Nr.: 27.702.895 von MichiMischtMit am 14.02.07 14:32:19... Marktdaten für EPO-Präparate [Bearbeiten]

      Als Therapeutikum rangiert EPO unter den zehn weltweit erfolgreichsten Medikamenten überhaupt, unter den Biopharmazeutika ist es der herausragende Blockbuster. Eprex/Procrit von Johnson & Johnson erzielte im Jahr 2004 3,6 Milliarden US-Dollar, Amgens Epogen 2,6 Milliarden Dollar und Roches NeoRecormon 1,7 Milliarden Dollar (Quelle: Chemical & Engineering News Nr. 83). Aranesp, das erste zugelassene EPO-Präparat der nächsten Generation, hat seit seiner Therapieeinführung eine durchschnittliche Zuwachsrate von rund 800 Millionen Dollar pro Jahr und wird die Umsatzzahlen der bisherigen Standardpräparate im Jahr 2007 voraussichtlich übertreffen. Bei den Nachfolgepräparaten Mircera und DynEpo wird mit anfänglichen Umsatzraten von 300 Millionen Dollar (DynEpo) oder 900 Millionen Dollar (Mircera) gerechnet. Der weltweite Bedarf an EPO zu Therapiezwecken ist bei weitem nicht gedeckt. Nach Schätzungen von Marktanalysten werden Hersteller von EPO-Präparaten im Jahr 2010, aufgrund zunehmender Indikationen und trotz der Einführung von Nachahmerpräparaten, insgesamt bis zu 17 Milliarden Dollar erwirtschaften (Quelle: Piribo – Online Buisiness Intelligence for the BioPharma Industry, Feb. 2005: Therapeutic Proteins, Strategic Report, Visiongain). Weltweit erhalten circa 350.000 Patienten rekombinantes EPO (Stand: 1999). Da sich die Umsatzzahlen der EPO-Präparate zwischen 1999 und 2005 mehr als verdreifacht haben, dürfte die Zahl der mit EPO behandelten Patienten entsprechend gestiegen sein...
      Avatar
      schrieb am 15.02.07 21:41:00
      Beitrag Nr. 257 ()


      :D
      Avatar
      schrieb am 16.02.07 20:18:27
      Beitrag Nr. 258 ()
      0,017 :eek::eek::eek:

      Volumen sieht gut aus :cool:
      Avatar
      schrieb am 16.02.07 20:32:50
      Beitrag Nr. 259 ()
      Antwort auf Beitrag Nr.: 27.759.530 von MichiMischtMit am 16.02.07 20:18:27Hoffentlich bleibt das auch so :D
      Avatar
      schrieb am 17.02.07 12:55:28
      Beitrag Nr. 260 ()
      Neue Shares :(

      http://edgar.brand.edgar-online.com/fetchFilingFrameset.aspx…

      ...CALCULATION OF REGISTRATION FEE

      Title of Securities
      to be Registered

      Amount to be
      Registered

      Proposed Maximum
      Offering Price

      Proposed Aggregate
      Offering Price

      Amount of
      Registration Fee
      Common Stock

      40,700,000 (1)

      $ 0.01475 (2)

      $ 600,325

      $ 64.23...

      ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


      http://www.investorshub.com/boards/read_msg.asp?message_id=1…

      OTC BB | Biotechs | DNAprint Genomics (DNAG) DNAG Quote/Level II - News - Quote - Chart

      Public Reply | Private Reply | Keep | Last Read Replies (2) | Next 10 | Previous | Next
      Posted by: Brothers In Arms
      In reply to: None
      Date:2/17/2007 12:25:09 AM
      Post #of 57002

      DNAPrint filed a new s-8 after the close today to issue over 40,800,000 shares.
      http://edgar.brand.edgar-online.com/default.aspx?cik=0001127…

      most of which will go to:RESOLVED, The Board agrees to issue up to 30,000,000 shares of the Company’s common stock to satisfy its obligations under the Agreement with Dr. Arthur J. Sytkowski.”

      Does anyone know what this is about? I will do more research, I just found this out now and wanted to post it.

      Scott...
      Avatar
      schrieb am 17.02.07 13:04:49
      Beitrag Nr. 261 ()
      http://www.tbo.com/news/money/MGBOAJZJMXE.html


      ...City Ups Its Part For Project By Merck, Moffitt
      Skip directly to the full story.

      By ELLEN GEDALIUS and CAROL GENTRY The Tampa Tribune

      Published: Feb 1, 2007

      ADVERTISEMENT
      Click here.
      More from this channel:

      Search for more information:

      TBO.com Site Search | Tribune archive from 1990

      TAMPA - Amid criticism it wasn't doing enough, the city of Tampa has agreed to increase its contribution to a planned medical research project involving drug maker Merck & Co. and the H. Lee Moffitt Cancer Center & Research Institute.

      The city is offering financial incentives totaling about $800,000, plus land valued at about $1.2 million, said Mark Huey, Tampa's economic development administrator. He would not disclose the land's location.

      The pledges of $2 million from the city and $20 million from the county plus land would be added to $15 million from the state. The proposed contributions must be approved by their governing bodies.

      Still, the public money is dwarfed by Merck's contribution of $95 million, consisting of $65 million in cash and $30 million in scientific services. Merck promised milestone payments of $13 million a year for five years.

      Merck has not made that information public, but it was disclosed in confidential documents made available to The Tampa Tribune, along with details on how the project will become "the world leader in personalized cancer care."

      The documents include the names of six companies that reportedly told Moffitt that they want to set up operations near the site of the joint project. Called M2Gen, it will be a for-profit subsidiary of Moffitt.

      The calls and letters followed the December announcement by then-Gov. Jeb Bush that Merck had agreed to make a significant investment in Hillsborough County as a partner with Merck, given financial incentives from the state and local governments.

      Initially, the city committed $500,000, prompting county commissioners to say that wasn't enough to help land such a substantial project.

      County Commissioner Mark Sharpe was pleased to hear that the city will up its portion. He hopes his colleagues on the commission move fast to secure the deal rather than bicker with the city over funding.

      "We need to look at this as good for the state, good for the county, good for cancer research," Sharpe said.

      Meanwhile, a request for $15 million in state funds to trigger a massive investment by Merck in Hillsborough County is on temporary hold pending answers to basic questions, a state lawmaker said.

      Sen. Rudy Garcia, co-chairman of the Legislative Budget Commission, said Wednesday that he is waiting for answers from Enterprise Florida, a public-private economic development group handling negotiations for the project, called M2GEN.

      Because he felt a briefing Jan. 23 in his office was insufficient, Garcia said he asked when the commission met Jan. 24 to have the matter held for a month. Garcia's questions concern the expected return on investment, timing on formation of the corporation, state and county contributions and whether other Moffitt projects would also come with financial requests.

      "I'm a simple kind of guy, and I just don't feel it's appropriate to rubber-stamp requests," said Garcia, R-Hialeah. "We should be looking at these thoroughly."

      Because of the project's complexity, it's taking longer to complete the documents to take to the Hillsborough Board of County Commissioners, said Economic Development Director Gene Gray. When the deal was negotiated, the county pledged $20 million, pending the board's approval. Gray said he had hoped to present the package next week, but it is unlikely to be ready that soon.

      Although the general form of the financial arrangements had become public in recent weeks, the details were kept confidential, which state law allows. However, a copy of the Moffitt business plan for M2GEN, which in the documents is called "Project Bold," was made available to the Tribune this week. Here are some highlights:

      •The project will create 165 direct jobs paying an average of $80,000 and 352 spinoff jobs.

      •No other cancer database has the capability to offer both research on tissues for drug development and a look-back feature to help the patients who donated tissues. Moffitt said it is at least three years ahead of any other institution in building such a database.

      •The speed-up in testing of new drugs will save money for pharmaceutical companies and pain for patients. Moffitt estimates the savings per drug at $35 million and says it will be able to tell whether a drug is responding in a particular patient within hours, instead of months.

      •Six companies have expressed interest in setting up operations near M2Gen. The documents list them as GE Healthcare, Genzyme, Applied Biosystems, Helicos, Nuclea and DNA Print.:eek:

      •Assuming the state invests $15 million in matching funds and $660,000 in tax refunds, it should double its investment in less than 10 years, based on a financial analysis...
      Avatar
      schrieb am 17.02.07 13:15:27
      Beitrag Nr. 262 ()
      http://www.bradenton.com/mld/bradenton/business/16502822.htm


      ...Posted on Sat, Jan. 20, 2007
      email this
      print this
      reprint or license this
      MANATEE FIRM MAKING LEAPS AT DNA'S DAWN
      Small specialty, global fame
      SARA KENNEDY
      Herald Staff Writer

      MANATEE - For a company whose lab work regularly solves crimes, has made international headlines about Margaret Thatcher's family heritage and is poised for growth at the scientific frontier of medicine, the vibe at DNAPrint Genomics, Inc., is surprisingly low-key.

      A single, hand-lettered sign scrawled with the company's name this week was the only indication it had moved during the holidays from downtown Sarasota to a larger building at 1621 W. University Parkway in southern Manatee County. The move was necessary to provide more space for its new subsidiary, DNAPrint Pharmaceuticals, Inc., officials said.

      The company's specialty is human genetics and, in particular, the genome, the content of all of an organism's hereditary information. It is a developer of genomics-based products and services.

      Its forensic work and genealogy tests have made international headlines in stories broadcast on National Public Radio and in publications like The New York Times, USA Today, CBS News and London's The Sunday Times.

      The company's findings figure in the investigation of sensational crimes, such as an effort to capture the so-called London Minstead Rapist, a serial rapist suspected of more than 90 assaults. Scotland Yard has turned to DNAPrint Genomics for help.

      "The investigation has drawn heavily upon forensic resources for psychological and geographic crime profiles," said Matthew J. Thomas, Ph.D., the company's senior scientist and manager of laboratory operations, after a trip to London last summer. Investigators used DNA information to analyze crime scene samples, but as far as Thomas knows, they have not yet made an arrest in the case.

      On Wednesday, Thomas was giving a tour of his firm's bright new laboratory and discussing one of its DNA testing products - AncestrybyDNA, a kit designed to reveal an individual's family heritage.

      For a $240 fee, clients can send a swab with tissue from inside the cheek that the company uses for a basic test, which pinpoints a person's genetic heritage based on four major anthropological groups: Native American, East Asian, sub-Saharan African and Indo-European. Depending on the results, additional tests may be ordered.

      The tests have produced some shocking results. One of the company's tests showed that Henry Louis Gates Jr., the famous black scholar, was half white. Another showed that Carol Thatcher, daughter of former British Prime Minister Margaret Thatcher, was of Middle Eastern descent.

      Each test takes a couple days of work, Thomas said.

      The company, with 20-some employees spread over the United States and Canada, stays connected to its far-flung staff through electronic communications rather than face-to-face interaction, said Emanuela I. Charlton, Ph.D., who works in customer service.

      It has employees in California, Pennsylvania, Colorado and Toronto, she said, adding that it also owns a percentage of a German company called BioFrontera.

      Richard Gabriel, DNAPrint Genomics' chief executive officer and president, who accepted shares of stock instead of cash compensation when he was hired in 2002, lives in Boston. Gabriel hired the company's chief medical officer and chairman of the board, Hector J. Gomez, M.D., Ph.D., who resides in Tampa.

      The company's annual revenues are in the $3 million range, Gomez said in a phone interview from Tampa. He said the money the company earns is sufficient to operate its labs, but acknowledged wearily that he is "in the process of raising money all the time" for research and development.

      During 2006, the company invested almost $3.2 million in research and development and $133,000 in patents to protect its technology rights, according to material the company provides investors.

      Gomez said he expects the new subsidiary, DNAPrint Pharmaceuticals, Inc., launched in October 2005, will help its bottom line. It will be ramping up in the company's new quarters and the technology Gomez expects it to develop would cut by half the 12 years and $800 million currently necessary to develop a new drug.

      "Now, with this technique, we can reduce the time of drug development by at least half to six years and decrease the cost by a significant number because we're minimizing mistakes," he explained.

      It will attempt to design drug regimens that go beyond the one-pill-fits-all concept.

      "With this technology, pharmaco-genomics, it allows us to take a sample of DNA from any patient and in the lab predict response - who is going to respond well, who will have side effects. Obviously, we can do that then by maximizing the efficiency of the drugs and minimizing the side effects, based on the person's genetic makeup," Gomez said.

      Both Gomez and DNAPrint Genomics will also be part of a massive research initiative announced last month by the H. Lee Moffitt Cancer Center & Research Institute of Tampa. The center said it would partner with an affiliate of Merck & Co., Inc. pharmaceutical company to expand biotechnology research with the goal of developing personalized medicine.

      Merck and Moffitt will form a for-profit company, called M2GEN, that will develop personalized cancer treatments using a patient's genetic profile.

      Researchers plan to compile a database of tumor tissue and other medical information to determine why some patients respond to a treatment and others do not. The database could grow to more than 30,000 patients within five years, officials said in announcing the partnership.

      "For a look at future, in 10 years, I believe you'll have (something similar to) a credit card in your pocket with all your information. It's your genetic makeup and the doctor will look at it and prescribe the medicine for you," said Gomez. "We are very excited about this."

      DNAPrint Genomics was founded by Tony Frudakis, Ph.D., and acquired by another company in 2000. In 2001, Frudakis teamed with other scientists to develop new genomics products with consumer, forensic and pharmaco-genomics applications, according to Securities and Exchange Commission documents.

      Since then, the company has acquired several other firms that brought scientific assets with them, such as Kenna Technologic Inc., which develops software for building computer models that mimic biological systems, and Ellipsis Biotherapeutics Corp., which specializes in genotyping and can analyze human, plant and animal tissue, SEC documents said.

      Last year, the company entered into an exclusive license agreement with Harvard College at Harvard Medical School, for research and development of a diagnostic test that would identify those at risk of developing vascular diabetic complications, SEC documents reported...
      Avatar
      schrieb am 17.02.07 14:29:46
      Beitrag Nr. 263 ()
      http://www.investorshub.com/boards/read_msg.asp?message_id=1…

      ...OTC BB | Biotechs | DNAprint Genomics (DNAG) DNAG Quote/Level II - News - Quote - Chart

      Public Reply | Private Reply | Keep | Last Read Next 10 | Previous | Next
      Posted by: Brothers In Arms
      In reply to: goliath65 who wrote msg# 56914
      Date:2/16/2007 6:29:54 AM
      Post #of 57008

      You are ignoring a potential revenue source. DNAG sponsored the Amber Alert Site. I know 100 families at my church that will register thier children to this new technology. Dnag has many short term revenue sources now. They also have big long term revenue sources also. PT401 will be big....BIG....pennys will turn into dollars....you will see..I know......
      Avatar
      schrieb am 17.02.07 14:48:39
      Beitrag Nr. 264 ()
      http://www.investorshub.com/boards/read_msg.asp?message_id=1…

      ...OTC BB | Biotechs | DNAprint Genomics (DNAG) DNAG Quote/Level II - News - Quote - Chart

      Public Reply | Private Reply | Keep | Last Read Next 10 | Previous | Next
      Posted by: stockhlder101
      In reply to: stockhlder101 who wrote msg# 56856
      Date:2/16/2007 5:12:17 AM
      Post #of 57009

      M2GEN is rolling! Like it or not!>
      http://www.redorbit.com/news/science/839603/he_holds_the_key…

      He Holds The Key To Cancer Research
      By Carol Gentry, Tampa Tribune, Fla.

      Feb. 13 --TAMPA -- Every few days, a Federal Express truck pulls into the loading dock at Moffitt Cancer Center & Research Institute with another delivery of tumor tissues, snap-frozen in liquid nitrogen and stored in Ziploc bags.

      A white-clad research technician signs for the cooler and takes it to the third floor, where each sample is assigned a bar-code number and stored in a freezer at -80 degrees Celsius until needed for research.

      The identity of the donor is fed into a file that becomes part of an encrypted data set accessible to only a trusted few on the team of Tyron Hoover, whom the hospital calls the "honest broker." He holds the key to which patients go with which genes.

      "He's the only one who can put the glue together, who can marry the data sets," says Edward Martinez, chief information officer for Moffitt. "It's like a giant jigsaw puzzle."

      Hoover, medical director for the tissue bank project, is both a doctor and a lawyer. He briefly worked for plaintiffs suing doctors, until realizing his heart lay in medicine, he said.

      As a board-certified pathologist, he's ideally suited to supervising an operation that analyzes, preserves and studies tissue samples. He uses his legal knowledge in dealing with issues of patient consent, research authorizations and compliance with federal privacy laws.

      Because of strict federal laws governing medical privacy, all hospitals are paying large sums for security as they transfer information to electronic records. Over the past four years, Martinez said, Moffitt has spent about $30 million for its system from Kansas City, Mo.-based Cerner Corp., of which about $10 million went into security.

      "We are as protected as any other hospital in the country -- or any financial institution," he said.

      More Than 3,000 Patients Have Given Consent

      Moffitt's challenge is especially great as it sets out to build the world's largest cancer tissue databank, which will contain genetic information from patients who received all their treatment elsewhere. The databank, part of Moffitt's Total Cancer Care project, will be developed jointly with Merck & Co. through a for-profit subsidiary called M2Gen.

      Discussions over the databank funding continue. Merck has agreed to pay $95 million in cash and in-kind contributions over five years in return for match money that still needs to be approved by various public bodies: up to $28 million in cash and land from Hillsborough County, $15 million from the state, and $2 million in cash and land from the city of Tampa.

      Meanwhile, Total Cancer Care is well under way. More than 3,000 cancer patients have given their consent for donation of their tissue to the databank since recruiting began about eight months ago, Hoover said. Moffitt Director William S. Dalton has said he hopes to have donations from 30,000 patients across the state within five years.

      Moffitt works with an extensive network of hospitals and physician groups in the state, and so far it has enacted formal agreements on Total Cancer Care with four: Morton Plant Hospital in Clearwater, Sarasota Memorial Health Care, Parrish Medical Center in Titusville, and Center for Cancer & Research in Lakeland, an affiliate of the Watson Clinic. Hoover said negotiations are under way with eight more groups in the state, but declined to identify them.

      Under the agreements, Moffitt pays the affiliates so that they can hire additional staff to process the tissues and paperwork for samples that will be sent to Moffitt for inclusion in the databank.

      The invitation to cancer patients to donate tissues for the project has to make clear that there is very little chance they will directly benefit, Hoover said. It will be at least a year and probably longer before researchers can match the genetic "fingerprints" from different patients and their individual cancers to treatments that will work.

      Or not. One purpose of the databank, Dalton has said, is to spare patients in the future from undergoing risky and painful treatments that will not benefit them.

      'We're In A Biomedical Evolution'

      Usually the one who invites the patient to participate is the surgeon who performed a biopsy and is about to remove a tumor, said oncologist Fred Schreiber at the Watson Clinic. That site has enrolled about 160 patients in Total Cancer Care so far, he said, with a wide spectrum of cancers.

      "We're in a biomedical evolution that's huge," Schreiber said. Using current knowledge of DNA and genetic proteins, by studying the tissue samples, "we'll redefine what cancer really is," he said.

      "We'll learn about new technologies, new treatments," he said. "We want to contribute to that effort because overall the goal is to cure cancer."

      Schreiber said he's not aware of any patients turning down the request to sign up for Total Cancer Care, but that could change. Until now, the tissue donation entailed no extra time or discomfort, since it was being collected at the time of surgery.

      Because it's important to do research on tissues from advanced cancers that are not operable, Schreiber said, patients who are in that group will be asked whether they are willing to go through an extra tissue-collection procedure in order to participate in Total Cancer Care.

      Shannon Bouchard, a 41-year-old pancreatic cancer patient from Lakeland who is undergoing both radiation and chemotherapy, says she knows the tissue she donated to Total Cancer Care during surgery in December isn't likely to help her. On the other hand, she said, she has a 16-year-old daughter and 11-year-old son, so she cares about the future.

      "If my daughter or grandchild or anyone else has [cancer someday], it will help them, possibly," Bouchard said. "I think it's a great idea."

      Just on the off-chance that a discovery comes in time to help her or someone like her, Moffitt has to have a way to reattach the name to the tissue sample. That's where Hoover comes in.

      He can pull up the encrypted database that bears the database of patients' names and match it to the one that bears the bar-code numbers for the tissue samples. Then Moffitt can get in touch with the patient -- assuming the patient has given permission for re-contact.

      They've tested the system against accidental or purposeful breach of confidentiality and found the risk is "almost zero," Hoover said. "It's not absolutely zero, but it's highly unlikely. We take every precaution to make sure that doesn't happen."

      Reporter Carol Gentry can be reached at (813) 259-7624 or cgentry@tampatrib.com.

      -----

      Copyright (c) 2007, Tampa Tribune, Fla...
      Avatar
      schrieb am 19.02.07 14:20:22
      Beitrag Nr. 265 ()
      Enforcement Expo 2007
      July 11 & 12, 2007
      I-X Center
      Cleveland, Ohio



      http://www.investorshub.com/boards/read_msg.asp?message_id=1…

      OTC BB | Biotechs | DNAprint Genomics (DNAG) DNAG Quote/Level II - News - Quote - Chart

      Public Reply | Private Reply | Keep | Last Read Replies (1) | Next 10 | Previous | Next
      Posted by: sam1933
      In reply to: ann441j who wrote msg# 57199
      Date:2/19/2007 2:24:48 AM
      Post #of 57220

      http://www.enforcementexpo.com/enex/events_conference.po;jse…

      2:00 PM The Evolution of DNA Technology in Investigative Case Work: Overview of DNAWitness 2.5 and Case Histories
      Matt Thomas, PhD
      DNAPrint Genomics Inc.


      Join Dr. Thomas for a fascinating look at a new forensic DNA investigative tool that is able to produce a rough physical description of a sample’s donor. The test determines the relative affiliation of a DNA sample to four populations, Sub-Saharan African, European, East Asian, and Native American. This type of analysis produces a Bio-Geographical Ancestry (BGA) profile of the sample based on their genetic heritage. This technology is distinct from the more common CODIS STR technology which requires a comparison of two samples to determine if the donors match or can be excluded. Information from the single sample can be compared to a database to further refine information regarding physical traits of the suspect, a process which greatly enhances the search for the suspect. This presentation will cover the technology and review casework where DNAWitness has proven valuable to the investigating officers.
      Avatar
      schrieb am 20.02.07 19:49:53
      Beitrag Nr. 266 ()
      :eek::eek::eek:

      Avatar
      schrieb am 20.02.07 22:03:36
      Beitrag Nr. 267 ()
      Avatar
      schrieb am 20.02.07 22:09:25
      Beitrag Nr. 268 ()
      Avatar
      schrieb am 21.02.07 20:27:04
      Beitrag Nr. 269 ()
      http://www.investorshub.com/boards/read_msg.asp?message_id=1…

      OTC BB | Biotechs | DNAprint Genomics (DNAG) DNAG Quote/Level II - News - Quote - Chart

      Public Reply | Private Reply | Keep | Last Read Next 10 | Previous | Next
      Posted by: stockhlder101
      In reply to: None
      Date:2/21/2007 4:32:37 AM
      Post #of 57490

      28mil M2GEN county vote today/15mil state thurs. M2GEN should get both in my opinion and we roll BIGGGGG!
      Many G's!
      Over .25 to may be .5 is my guess.......
      SOOOOOOOOOOOoooooooooooon!
      Just my opinion.
      Avatar
      schrieb am 22.02.07 00:35:05
      Beitrag Nr. 270 ()
      schütten...schütten....schütten und nur nicht an die Kohle denken. KZ: 0

      Benn
      Avatar
      schrieb am 22.02.07 00:45:08
      Beitrag Nr. 271 ()
      Antwort auf Beitrag Nr.: 27.888.940 von benn1 am 22.02.07 00:35:05was meinst du damit??
      Avatar
      schrieb am 23.02.07 02:35:19
      Beitrag Nr. 272 ()
      Ich meine, dass dieser Hype so schnell vorbei ist, wie er gekommen ist.
      DNAG ist ein Cashburner.
      Der Kursanstieg könnte auf einem im ersten Quartal versprochenen erfolgreichen Test bei Biofrontera beruhen.

      Benn
      Avatar
      schrieb am 28.02.07 19:46:45
      Beitrag Nr. 273 ()
      Avatar
      schrieb am 06.03.07 18:19:34
      Beitrag Nr. 274 ()
      Antwort auf Beitrag Nr.: 28.033.395 von Qork am 28.02.07 19:46:45Na endlich mal wieder aufwärts :D Nur weiter soooooooo
      Avatar
      schrieb am 07.03.07 12:34:06
      Beitrag Nr. 275 ()
      UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549
      --------------------------------------------------------------------------------
      FORM 8-K
      --------------------------------------------------------------------------------
      CURRENT REPORTPursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934Date of Report (Date of earliest event reported) February 27, 2007DNAPrint Genomics, Inc.
      (Exact name of registrant as specified in its charter)UT 000-31905 59-2780520
      (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
      1621 West University Parkway - Sarasota, FL 34243
      (Address of principal executive offices & zip code) Registrant's telephone number, including area code: (941) 366-3400
      (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
      --------------------------------------------------------------------------------



      Item 1.01 Entry into a Material Definitive Agreement.

      See Item 2.01 below.


      Item 2.01 Completion of Acquisition or Disposition of Assets.

      On February 27, 2007, the Registrant entered into a contract to dispose of, and completed the disposition of, 373,324 shares of Biofrontera AG. The contract, with Matchmakers Consulting AG, a Swiss corporation, provides for the payment to the Registrant of an aggregate of €4,443,240 (approximately $5.9 million). The DZ Bank AG Deutsche Zentral-Genossenschaftsbank has released the Registrant from the lock-up agreement regarding the shares after the Swiss corporation entered into a similar lock-up agreement. An installment of €500,000 (approximately $659,000) was paid simultaneously with the execution of the agreement. The remainder of the purchase price will be paid in seven monthly installments of €500,000 (approximately $659,000) each in the months of March through September, 2007, with a final installment of €443,240 (approximately $584,000) due on October 31, 2007.



      In addition, by October 31, 2007, the Registrant has the right to irrevocably announce a repurchase of any or all of the shares sold in this transaction at a purchase price of €16.13 per share. If exercised in full, this repurchase right would require payment of an aggregate repurchase price of €6,005,586 (approximately $7.9 million). The repurchase would then be executed between October 31, 2007 and March 31, 2008.
      ExhibitsNone


      --------------------------------------------------------------------------------
      SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



      Date: March 5, 2007 By: /s/ Richard Gabriel
      Richard Gabriel
      President
      Avatar
      schrieb am 13.03.07 12:49:33
      Beitrag Nr. 276 ()
      Antwort auf Beitrag Nr.: 28.033.395 von Qork am 28.02.07 19:46:45Da wird einem ja übel :D

      Wars das schon wieder?
      Avatar
      schrieb am 16.03.07 17:40:38
      Beitrag Nr. 277 ()
      DNAG - Das wars dann wieder. Assets verkaufen und wieder bischen Cash zum Verbrennen in der Kasse.

      KZ: 0

      Benn
      Avatar
      schrieb am 16.03.07 21:25:06
      Beitrag Nr. 278 ()
      Antwort auf Beitrag Nr.: 28.331.556 von benn1 am 16.03.07 17:40:38Sieht im Moment wirklich so aus :(

      Schade eigentlich
      Avatar
      schrieb am 20.03.07 19:56:44
      Beitrag Nr. 279 ()
      Zocker springen ab. Neue Lows nur eine Frage von Tagen.

      Benn
      Avatar
      schrieb am 21.03.07 16:40:14
      Beitrag Nr. 280 ()
      -18%

      Die faire Bewertung liegt bei 0,006$ / share...und da gehts auch erst mal hin.


      Langfristig KZ: 0
      - keine gewinnbringenden Produkte.
      - reine Forschungsbude
      - und für irgend welche Rassentheorien sind selbst die verrückten Amis nicht zu begeistern.
      Avatar
      schrieb am 22.03.07 12:09:53
      Beitrag Nr. 281 ()
      DNAPrint(TM) Genomics Reports Financial Results for Fourth Quarter and Full-Year 2006
      DNAPrint(TM) Genomics, Inc. (OTCBB: DNAG) today issued a commentary on its financial results for the fourth quarter and for the fiscal year ended Dec. 31, 2006, which were filed on March 15, 2007.

      Revenue for the fourth quarter of 2006 was $525,646, an increase of 42.4% over revenue of 369,033 for the fourth quarter of 2005. Revenue for the year ended Dec. 31, 2006, was $2.4 million, an increase of 90.7% over revenue of 1.3 million for fiscal 2005.

      "We are pleased to have achieved this growth in revenues," stated DNAPrint(TM) Genomics President and Chief Executive Officer Richard Gabriel. "The increase over revenues from 2005 is directly attributable to an approximate 330% increase in revenue from our genotyping business, which derives mainly from the purchase of Ellipsis Biotherapeutics in late 2005, and 73% increase in revenue from Ancestry products."

      2006 Highlights and Milestones

      -- Q4 revenue of $525,000, an increase of 42% over last year

      -- Year-end revenues of $2.4 million, an increase of 91% over 2005

      -- Q4 Genotyping revenue of $170,000, an increase of 643% over Q4 2005

      -- Full-year Genotyping revenue of $770,000, an increase of 330% over
      full-year 2005

      -- Full-year revenue of $1.6 million for Ancestry products, an increase
      73% over 2005

      -- Invested $6.4 million in research and development of our products
      during 2006

      -- Two patents granted and significant progress made on research into new
      therapies for statin-induced myalgia and depression

      -- Investment in Biofrontera shares were recorded at $7.9 million at
      yearend as Biofrontera went public during October 2006


      In 2006, research and development costs increased to $6,427,115 from $2,122,383 in 2005, an increase of 202.8%. The increase in research and development expense resulted primarily from research in various projects in the development pipeline, including DNAPrint(TM) Pharmaceutical's EPO project, the ADHD project, the Statinome project, the CD59 diabetes project, the post-operative nausea and vomiting (PONV) project and various amounts invested in research samples used to expand the current product lines.

      "We are certainly pleased that so many of our existing products have found acceptance in the marketplace," stated Mr. Gabriel. "We are particularly excited that two patents were granted to DNAPrint(TM) during 2006 -- one for identifying links between gene sequences and medical traits and another for the discovery of a genetic marker for statin-induced myalgia. We look forward to the successful completion of other research projects underway, especially the PT 401 'Super' EPO Dimer for the treatment of anemia, which is undertaken with Harvard Medical School's Beth Israel Deaconess Hospital in Boston. We also are pleased to continue support of the Statinome project for the detection of myalgia, or severe muscle pain, in certain patients, and the Ovanome project, a genetic test for predicting an ovarian cancer patient's response to some first-regimen chemotherapy."

      Mr. Gabriel continued, "We have also made rapid progress in funding the development of the CD59 diabetic test product, and we are excited about the new results that will be published either second or third quarter of this year. Diabetes is the number one health crisis facing the U.S. and our work with Harvard Medical School's Dr. Jose Halperin and Dr. Michael Chorev on the CD59 test, is extremely exciting to us and the researchers on both teams."

      DNAPrint kept its selling, general and administrative costs increased to only $3,194,122 compared to $2,864,548 for the same period in the prior year, an increase of only 11.5%.

      DNAPrint Genomics, Inc. formed a wholly owned subsidiary in 2005, known as DNAPrint Pharmaceuticals, Inc. for the development of diagnostic and pharmaceutical products. "We are exploring funding alternatives for DNAPrint(TM) Pharmaceuticals, including venture capital, spin-out and licensing and partnering, because the continued funding by the parent is becoming more difficult. We have sold the Biofrontera shares during late 2006 and early 2007 to give us some much-needed short-term funding. We have received proceeds of $1.8 million through February and will receive 500,000 euros (approx. $0.6 million) a month from March through September and 443,240 euros (approximately $.6 million) in October. This will provide us with a source of funding until we get additional funding secured. We hope to have a funding strategy in place by the second half of 2007 which will alleviate the financial burden on DNAPrint(TM) Genomics, Inc.," stated Mr. Gabriel.

      "Clearly, our challenge going forward is to control costs, keep our projects running, continue the sales momentum that we have achieved with the ancestry and genotyping products, and to find ways to increase genotyping and general fee income," stated Mr. Gabriel. "To that end, one of our endeavors for 2007 will be to join with law enforcement agencies nationwide in supporting legislation before Congress that provides for the full funding of DNA testing in crime scene investigations. Currently, DNA test reimbursements are at a low percentage of real costs. We need to convince our lawmakers that money spent on DNA testing can yield returns in the form of identifying and apprehending suspects and obtaining convictions. We are also aggressively pursuing business in the health care arena using our underlying DNA and diagnostic technologies to help clinicians advance diagnostics and therapeutics in addition to pursuing our regular business interests of DNA testing and services" he stated.

      About DNAPrint(TM) Genomics, Inc.

      DNAPrint(TM) Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint(TM) Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint(TM) is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

      Company Contact:
      Richard Gabriel
      CEO and President
      941-366-3400
      -or-
      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848





      Source: Market Wire (March 22, 2007 - 7:00 AM EDT)

      News by QuoteMedia
      www.quotemedia.com
      Avatar
      schrieb am 22.03.07 15:19:30
      Beitrag Nr. 282 ()
      Avatar
      schrieb am 09.04.07 14:51:22
      Beitrag Nr. 283 ()
      DNAPrint(TM) Genomics' Advancements in PT-401 and Statinome Presented at Clinical Pharmacology Conference
      DNAPrint(TM) Genomics, Inc. (OTCBB: DNAG) today reported that several advancements in its proprietary DNA research on PT-401 and Statinome formed the basis for three papers that were presented by DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D., and Neil Kabrun, Ph.D., a senior scientist with the DNAPrint Computational Biology Group, at the recent annual meeting of the American Society for Clinical Pharmacology and Therapeutics held in Anaheim, Calif.

      "Presenting papers at conventions is an important part of the research process, because it gives one's peers in the scientific community a chance to review and comment on work that is being done, which ultimately may lead to its acceptance as sound science," Dr. Gomez said. "Presenting these specific papers at the meeting of the Society for Clinical Pharmacology and Therapeutics is an important step in advancing DNAPrint's research agenda and brings us closer to the day when DNAPrint products based on PT-401 and Statinome may be introduced to the marketplace."

      In one study, PT-401 was shown to be more potent and longer acting than epoetin alfa, a form of recombinant human erythropoietin currently in the market for the treatment of anemia. In another study, EPOFusion(TM), DNAPrint's proprietary, pre-clinical computer model for testing the characteristics and mechanisms of EP-401, was successfully used to predict a patient's responses to epoetin alfa, and will be used to predict a patient's response to PT-401. All PT-401 experiments will be first run through the computer using the EPOFUSION model, thus facilitating the preparation of clinical protocols and increasing its possibilities of succeeding during the clinical development of PT-401 in patients with anemia.

      A third paper detailed the discovery of genetic variations that form the basis of Statinome, a predictive diagnostic test that will allow the physician to select an alternative therapy that would avoid statin-induced muscle effects in patients.

      PT-401 is a "Super EPO," a more powerful form of Erythropoietin, a well-known drug used for the treatment of anemia. PT-401 is a potential competitor in the EPO market that currently exceeds $10 billion and is rapidly growing.

      Statinome is a protocol that can be used to detect the possibility of myalgia, or severe muscle pain, in patients who take statins, which are drugs that are used to lower cholesterol. Myalgia may also lead to rhabdomyolysis, which is a breakdown of muscle fibers that frequently results in kidney damage and is a potentially fatal side effect.

      About DNAPrint(TM) Genomics, Inc.

      DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

      Company Contact:
      Richard Gabriel
      CEO and President
      941-366-3400
      -or-
      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848





      Source: Market Wire (April 4, 2007 - 7:00 AM EDT)

      News by QuoteMedia
      www.quotemedia.com
      Avatar
      schrieb am 12.04.07 00:16:34
      Beitrag Nr. 284 ()
      Nicht nur, dass sie Biofronteraanteil geschüttet haben. Jetzt gehts weiter mit eigenen Aktien. Eigentlich sind sie ja schon tot. Aber interessant, wie lange so eine Leiche noch zuckt.

      KZ: 0

      Benn
      Avatar
      schrieb am 12.04.07 09:17:37
      Beitrag Nr. 285 ()
      DNAPrint(R) Genomics Filing SB-2
      DNAPrint® Genomics, Inc. (OTCBB: DNAG) today announced that it will be filing a registration statement with the Securities and Exchange Commission to register 150,000,000 shares to be issued under an Investment Agreement with Dutchess Private Equities Fund, Ltd. ("Dutchess"). The Dutchess Agreement provides that, from time to time, DNAPrint may deliver a notice to Dutchess and Dutchess will purchase DNAPrint shares based upon the parameters of the agreement.

      Currently, DNAPrint has effective a registration statement covering approximately 640,000,000 shares issuable under an existing Dutchess agreement that expires May 17, 2007. Shares can be issued under this agreement through May 17, 2007, but once the agreement has expired, none of those 640,000,000 registered shares can be issued. More details on the filing can be found under the Company's name at www.sec.gov.

      "We are pleased to continue our relationship with Dutchess. We are in the process of obtaining additional funding for our research and development activities of our subsidiary, DNAPrint Pharmaceuticals, Inc., but we continue to use the Dutchess funding as well," stated DNAPrint® President and Chief Executive Officer, Richard Gabriel.

      About DNAPrint® Genomics, Inc.

      DNAPrint® Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint® Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWitness(TM), RETINOME(TM), Ancestry ByDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

      Company Contact:
      Richard Gabriel
      CEO and President
      941-366-3400
      or
      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848





      Source: Market Wire (April 11, 2007 - 7:00 AM EDT)

      News by QuoteMedia
      www.quotemedia.com
      Avatar
      schrieb am 16.04.07 09:34:36
      Beitrag Nr. 286 ()
      :eek:
      Avatar
      schrieb am 16.04.07 11:31:14
      Beitrag Nr. 287 ()
      Da hat sich wohl einer vertippt???

      Geld
      0,006

      Brief
      0,080


      Zeit
      16.04.07 11:05:54

      Geld Stk.
      200.000

      Brief Stk.
      200.000
      Avatar
      schrieb am 25.04.07 18:43:04
      Beitrag Nr. 288 ()
      dnag - alles im Plan. Bald mit neuen Lows. Im Sinne ihrer Aktionäre handeln die jedenfalls nicht. Die kämpfen ums nackte Überleben.

      KZ: 0

      Benn
      Avatar
      schrieb am 27.04.07 13:25:17
      Beitrag Nr. 289 ()
      Alles oder nichts! *grins*
      Hoffe, sie finden immer wieder mal Kapitalgeber, deren Geld sie vernichten können, um zu überleben ...
      Viel mehr können Sie den Wert aber nicht mehr verwässern.
      Bisher habt ihr die Forschung und deren Gehälter bezahlt.
      Mit langem Atem wird's vielleicht noch ... (Müsst ihr aber alt werden ...)
      Denke jedoch, man kann die Aktie in Ruhe beobachten und bei "vernünftigen" News, die zeigen, dass das Ongoing mal länger als 3 Mon. gesichert ist, vorsichtig einsteigen oder zusehen, wie das Papier von der Börse verschwindet ...
      Bisher sind die Jungs von DNAG ein mittelfristiges Finanzierungskonzept jedoch schuldig geblieben und mit der Kursentwicklung der letzten Jahre, finden die auch keine Geldgeber mehr. Deutlich Spirale nach unten, wie jede Kapitalerhöhung auf dem Rücken der bisherigen Anleger gezeigt haben ...
      Viel Spass!
      Avatar
      schrieb am 30.04.07 07:48:45
      Beitrag Nr. 290 ()
      DNAPrint Genomics President & CEO Richard Gabriel Is Interviewed on MN1
      DNAPrint Genomics, Inc. (OTCBB: DNAG) President and Chief Executive Officer Richard Gabriel was featured in an exclusive Market News First (MN1) interview on Thursday, April 26th, 2007 at 1:30 PM CST.

      Chief Executive Officer Richard Gabriel spoke with MN1 host Rich Hancock on www.mn1.com about the Company's innovative and cutting edge technology that aids law enforcement crime scene investigation (CSI) forensics, consumer applications in genealogy ancestry/genetic testing and its pharmaceutical and diagnostic applications.

      During the interview Mr. Gabriel highlighted the Company's recent advances in its pharmaceutical and diagnostic, and spoke about its successes in both law enforcement and the growth market of DNAPrint's consumer oriented products.

      The interview was podcast and will be archived for six months at the MN1 site, www.mn1.com.

      About MN1.com

      Market News First is an online, market news provider that brings investors current news on the market. Market News First is the only online, live IPTV web site that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE. Through daily, live interviews, we bring you up to date on all the established companies and inform the investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans.

      About DNAPrint Genomics, Inc.

      DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

      Company Contact:

      Richard Gabriel
      CEO and President
      941 366-3400
      -or-
      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848





      Source: Market Wire (April 27, 2007 - 7:00 AM EDT)

      News by QuoteMedia
      www.quotemedia.com
      Avatar
      schrieb am 01.05.07 12:53:25
      Beitrag Nr. 291 ()
      Avatar
      schrieb am 01.05.07 12:54:15
      Beitrag Nr. 292 ()
      Antwort auf Beitrag Nr.: 29.080.823 von Laffel-2 am 01.05.07 12:53:25http://app.quotemedia.com/quotetools/showFilingOutline.go?sy…
      Avatar
      schrieb am 01.05.07 17:47:54
      Beitrag Nr. 293 ()
      Sauber. Neues Jahrestief.
      Dodesspirale. KZ: 0

      Benn
      Avatar
      schrieb am 11.05.07 19:47:26
      Beitrag Nr. 294 ()
      Aha. In dem Sabbermarkt wird bei DNAG weiter geschüttet. Heute mit gutem Volumen. Fairen Wert von $0,006 haben sie intraday auch schon angetipt.

      Aber die Geldverbrennung bei DNAG geht ja weiter, so dass die 0,006 mittelfristig auch nur noch Makulatur sind.

      KZ: 0

      Benn
      Avatar
      schrieb am 14.05.07 16:16:35
      Beitrag Nr. 295 ()
      The New Medicine: Executives From Three Fast-Evolving Bio-Med Companies Update The Wall Street Reporter Community on How They Are Making Tomorrow's Therapies a Reality
      NEW YORK, May 14, 2007 (PRIME NEWSWIRE) -- Wall Street Reporter Magazine has just published exclusive interviews with executives from INNOVIVE Pharmaceuticals (OTCBB:IVPH), DNAPrint(tm) Genomics Inc. (OTCBB:DNAG), and GangaGen Inc. (Private Equity) -- all companies that are poised to take their businesses to the next level.

      All three interviews are now available at http://wallstreetreporter.com in streaming audio, MP3, and text format -- all free of charge.

      In the oncology space, Steven Kelly, President and CEO of INNOVIVE Pharmaceuticals (OTCBB:IVPH) tells Wall Street Reporter senior analyst Todd Santorelli that a recent $15 million equity financing round will help push his company's four distinct clinical-stage programs forward through the clinic.

      Areas covered in especially extensive detail include:


      * How the company plans to use the proceeds of a recent $15 million
      equity round to advance its entire pipeline. "These funds will
      allow us to proceed with drug development on all four of our
      clinical-stage compounds," he says.

      * His lead program's billion-dollar potential as a treatment for
      chronic myelod leukemia (CML), a market where Novartis Gleevec has
      already created a $2.5 billion market. "This drug will compete in
      the CML marketplace, not necessarily head-to-head with Gleevec,
      but it'll be looking at the Gleevec-refractory patient population."

      * How the company's follow-up programs for various leukemias and
      small-cell cancers create revenue opportunities in the $100 million
      to $500 million range.

      * Existing and prospective relationships with overseas pharma and
      academic organizations.

      "We have a more robust portfolio of drugs," he says. "We have four distinct shots on goal. All of them are legitimate shots on goal within the next three years."

      From the emerging area of pharmacogenomics, Richard Gabriel, CEO of DNAPrint(tm) Genomics Inc. (OTCBB:DNAG), tells Wall Street Reporter senior analyst Todd Santorelli that his company is at the forefront of efforts to create "theranostics," combinations of drugs with genetic diagnostic tools to help clinicians tailor treatment to patients' genetic makeup.

      "People are trying to figure out what personalized medicine means," he says. "We believe we've already accomplished that."

      In the exclusive interview, Mr. Gabriel covers the following topics in particular detail:


      * The company's existing genetic ancestry testing and forensic
      genomics businesses.

      * His strategic focus on licensing and technology. "One lead compound
      is being evaluated by NIDA (the National Institute on Drug Abuse),"
      he says. "We have two other compounds which we've identified for
      attention deficit disorder as well as depression."

      * How the company's technology has already been validated and now
      commercialization is simply a matter of capital. "Our product is
      more effective, less toxic, and we will link it with genetic
      ancestry as well as other diagnostics to avoid patient use
      problems."

      Finally, GangaGen Inc. (Private Equity) is getting close to bringing its novel anti-microbial technology to bear on the problem of drug-resistant infectious disease, says Dr. Rainer Engelhardt, the company's CEO. "In the area of antibiotic-resistant bacterial disease, investors should see us not only as an existing leader, but as a continuing leader," he tells Wall Street Reporter's Todd Santorelli. "We do anticipate being on the market with a phage product as early as next year."

      Key areas covered in the exclusive interview include:


      * An overview of GangaGen's unique technology, which utilizes the
      bacteria-eating ability of naturally-occurring microbes to fight
      the growing clinical problem of acquired antibiotic resistance.
      "Antibiotic-resistant bacteria and the infectious diseases
      associated with them generally speak to a global problem,"
      Dr. Engelhardt says. "It can be a very serious healthcare issue."

      * The company's secure intellectual property position.

      * An established partnership with Eli Lilly & Co. (NYSE: LLY) animal
      health subsidiary Elanco to eliminate E. coli contamination in
      meat products.

      * Dr. Engelhardt's confidence that the company should bring a program
      into the clinic within the next year.

      "Our short- to mid-term vision is to take our animal health products, the leading products in terms of their development path, into the market," he tells Wall Street Reporter. "We anticipate having a product on the market by next year if all goes well on the regulatory side."

      About Wall Street Reporter

      Wall Street Reporter (Est. 1843) helps smart investors connect with exciting companies, through our website, magazines, and conferences. We're probably best known for our exclusive interviews with industry-leading CEOs and the world's top investment experts.

      Wall Street Reporter produces in-depth, unbiased, unfiltered interviews that deliver a first-hand, straight-from-the-source perspective. This enables our audience to make intelligent and informed investment decisions.

      About INNOVIVE Pharmaceuticals

      INNOVIVE Pharmaceuticals is a biopharmaceutical company headquartered in midtown Manhattan. Our mission is to acquire, develop, and commercialize novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. INNOVIVE is grounded in scientific and technical excellence. We are committed to creating value for shareholders, employees, caregivers and patients who use our products.

      About DNAPrint(tm) Genomics Inc.

      DNAPrint(tm) Genomics Inc. is a cutting-edge company. We are concentrating our efforts in four distinct areas: pharmacogenomics, forensics, genotyping, and consumer products. Our aim is to continue to research and develop novel products and services in each of these market areas and to be a leader in genomic-based technologies.

      About GangaGen Inc.

      GangaGen is a privately held, Delaware-incorporated biotechnology company focused on the research, development and commercialization of proprietary bacteriophage-based treatments for the control and elimination of bacteria that cause human disease and as a solution to the worldwide problem of antibiotic resistance. The company's subsidiary in India (GangaGen Biotechnologies Pvt. Ltd) focuses on bacteriophage research and the development of phage preparations for direct human applications. The Canadian subsidiary (GangaGen Life Sciences Inc.) focuses on developing phage preparations to eliminate from food animals and their environment bacteria potentially harmful to humans before they can be transmitted to humans. Headquarters for GangaGen Inc. is in San Francisco, California.

      Forward-Looking Statements

      Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue," or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The company has no obligation to update these forward-looking statements.

      CONTACT: Wall Street Reporter Magazine
      Jack Marks, CEO and Publisher
      212-363-2600 ext 260
      www.wallstreetreporter.com

      INNOVIVE Pharmaceuticals
      Steven Kelly, President and CEO
      212-716-1810
      www.innovivepharma.com

      DNAPrint(tm) Genomics Inc.
      Richard Gabriel, Chief Executive Officer
      941-366-3400
      www.dnaprint.com

      GangaGen Inc.
      Dr. Rainer Engelhardt, Chief Operating Officer
      650-856-9118
      www.gangagen.com



      Source: PrimeNewswire (May 14, 2007 - 10:01 AM EDT)

      News by QuoteMedia
      www.quotemedia.com
      Avatar
      schrieb am 18.05.07 14:23:40
      Beitrag Nr. 296 ()
      Frankfurt gerade 125 % plus :laugh::laugh:
      Avatar
      schrieb am 23.05.07 01:45:06
      Beitrag Nr. 297 ()
      25. Juni HV....Unterlagen durchlesen und lachen.

      Habt ihr Hoffenden schon die Anteilsmehrheit an dem Laden?
      Bei 1024 Aktionären in common stocks ist die Frage nicht ganz unberechtigt.

      ca. $8Mio in Cash+Assets.
      ca. $13Mio Schulden
      ca. 700000$ Gewinn aus op. Geschäft 2006

      Forschungskosten weiter steigend angekündigt.
      Nix in der Pipeline, was sich in absehbarer Zeit vermarkten läßt.


      Dieses Jahr überlebt die Klitsche nicht. *lol*

      Benn
      Avatar
      schrieb am 23.05.07 07:46:19
      Beitrag Nr. 298 ()
      Antwort auf Beitrag Nr.: 29.428.149 von benn1 am 23.05.07 01:45:06Mich wundert das Dich dieser Threat überhaupt interessiert?????

      Und wenn DNAG pleite geht, dann ist es eben so... Wenn nicht, dann eben anders... wir werden es noch erleben... hoffe ich :D
      Avatar
      schrieb am 24.05.07 10:47:44
      Beitrag Nr. 299 ()
      Ich schaue da drauf, weil ich auch noch paar Stück habe. Bezogen auf meinen Einstand ist es für mich jetzt schon ein Totalverlust.

      Benn
      Avatar
      schrieb am 24.05.07 11:21:11
      Beitrag Nr. 300 ()
      Antwort auf Beitrag Nr.: 29.447.434 von benn1 am 24.05.07 10:47:44Dann gehts uns ja fast gleich... Nur das ich bei 0,009 eingestiegen bin und einen Teil wieder verkauft habe als sie gestiegen sind... Den Rest lasse ich mal liegen... man kann ja nie wissen...
      Avatar
      schrieb am 05.06.07 12:21:06
      Beitrag Nr. 301 ()
      Avatar
      schrieb am 13.06.07 13:25:11
      Beitrag Nr. 302 ()
      Moin zusammen!

      Kennt die jemand von Euch? http://www.cenimed.de/wDeutsch/index.shtml

      Produktportfolio hört sich teilweise recht ähnlich an!

      Gruß,

      g4
      Avatar
      schrieb am 19.06.07 11:28:16
      Beitrag Nr. 303 ()
      DNAPrint(R) Genomics Releases EuroDNA(TM) 2.0
      Powerful Ancestry Analysis Test Uses Over 1,300 Ancestry Indicator Markers
      DNAPrint® Genomics (OTCBB: DNAG) today announced the release of the long-awaited EuroDNA(TM) 2.0 (http://ancestrybydna.com/welcome/productsandservices/eurodna… ancestry indicator, which complements DNAPrint®'s powerful line of ancestry testing products.

      Richard Gabriel, Chief Executive Officer of DNAPrint® Genomics, sees many applications for EuroDNA(TM) 2.0. "Our customers have been requesting a more in-depth test, and we are excited to be able to give them our EuroDNA(TM) 2.0 test, which delivers more specific bio-geographical ancestry categories than our previous tests," Mr. Gabriel said.

      DNAPrint®'s EuroDNA(TM) 2.0 clarifies European sub-ancestry by using 1,349 European Ancestry Informative Markers (AIMs). This test reports a person's proportional basic continental European ancestry using several categories: Southeastern Europe (Armenian, Jewish, Greek and some Italians); Iberian (Spanish, Portuguese); Basque (Spanish/French Pyrenees border); Continental European (German, Irish, English, Polish, Some French and Italian); and North Eastern European (Finnish). The EuroDNA(TM) 2.0 test is by far the most advanced genetic ancestry test yet to be offered to the public.

      EuroDNA(TM) 2.0 provides more information than DNAPrint(TM)'s primary genealogy product, AncestryByDNA(TM) 2.5 (http://www.ancestrybydna.com/), which is a pan-chromosomal assay for genetic ancestry that uses just 176 AIMs. The new EuroDNA(TM) 2.0 test is also expected to provide greater sensitivity and accuracy than EuroDNA(TM) 1.0, which employed 320 AIMs. Some individuals who take AncestryByDNA(TM) 2.5 and/or EuroDNA(TM) 1.0 will find interesting, unexpected results and may desire to obtain the additional precision provided by EuroDNA(TM) 2.0's different, more extensive marker set.

      Using complex statistical algorithms, AncestryByDNA(TM) 2.5 by itself can determine with confidence which of the four major bio-geographical ancestry groups -- sub-Saharan African, European, East Asian or Native American -- constitutes a person's genetic background. The test also determines the relative percentages in cases of admixed peoples. It is a useful method for those individuals or groups interested in obtaining a deeper understanding of their ancestry and lineage, or for certain people (i.e., some adoptees of mixed heritage) learning about their genetic ancestry.

      "European" ancestry from AncestryByDNA(TM) 2.5 actually refers to a type of ancestry shared by people who derived from the fertile crescent of the Middle East some 50,000 years ago and spread to occupy Europe, the Middle East, parts of Eurasia and South Asia.

      About DNAPrint(TM) Genomics, Inc.

      DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

      Company Contact:
      Richard Gabriel
      CEO and President
      941-366-3400

      -or-

      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848





      Source: Market Wire (June 18, 2007 - 8:24 AM EDT)

      News by QuoteMedia
      www.quotemedia.com
      Avatar
      schrieb am 19.06.07 17:39:37
      Beitrag Nr. 304 ()
      Das sind leider fast nur reine Fluff-News; ohne großen Inhalt!
      Sieht man auch am Kurs und am momentanen Umsatz: Fast Null.

      Wenn da nicht bald was Heftiges möglichst im Zusammenhang mit M2GEN kommt, sehe ich schwarz für unser Invest.

      Bin mal gespannt auf die Gesellschafter-Versammlung demnächst.
      Wenn da nur im geringsten ein neuer Resplit angedeutet wird, bin ich sofort wieder raus!

      Gruß Michi
      Avatar
      schrieb am 21.06.07 10:57:46
      Beitrag Nr. 305 ()
      June 20, 2007 - 7:00 AM EDT

      close Email this News Article
      Your Name
      Your Email
      Friend's Name
      Friend's Email
      Receive Copy: yes

      DNAG 0.0072 0.00

      Today 5d 1m 3m 1y 5y 10y



      DNAPrint(R) Genomics to Present at ValueRich Small-Cap Financial Expo
      Company Sponsors Booth; Presentation to Be Webcast
      DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that President and Chief Executive Officer Richard Gabriel will present an overview of the Company to investors at the ValueRich Small-Cap Financial Expo on Thursday, June 21 at 11:40 a.m. Eastern time at the W New York Hotel, 541 Lexington Ave., in New York City.

      The twenty-minute presentation will be webcast live at: http://www.visualwebcaster.com/ValueRich/40379/event.html, where it will be archived for one year after the event. The Company is also sponsoring a table at the Expo at which senior management will be available throughout the day.

      For more information about attending the ValueRich Small-Cap Financial Expo, please visit: http://www.ivaluerich.com/expo.php.

      About ValueRich, Inc.

      ValueRich, Inc. operates various online and offline media-based properties for corporate and financial professionals, including ValueRich magazine (http://ivaluerich.com/magazine.php); the large-scale ValueRich Small-Cap Financial Expos (http://ivaluerich.com/expo.php) and the industry-wide online financial community iValueRich.com (http://www.ivaluerich.com/). The Company's corporate mission is to create the world's largest and most active community of financial professionals and small-cap public company executives through its integrated portfolio of products and services.

      About DNAPrint Genomics, Inc.

      DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

      Company Contact:
      Richard Gabriel
      CEO and President
      941-366-3400

      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848





      Source: Market Wire (June 20, 2007 - 7:00 AM EDT)

      News by QuoteMedia
      www.quotemedia.com
      Avatar
      schrieb am 26.06.07 16:25:16
      Beitrag Nr. 306 ()
      Was geht hier :eek: :eek:

      Avatar
      schrieb am 26.06.07 16:31:56
      Beitrag Nr. 307 ()
      Antwort auf Beitrag Nr.: 30.327.822 von Laffel-2 am 26.06.07 16:25:16:laugh: Schau mal in meinen Thread; vielleicht erfährst Du da was? :laugh:
      http://www.wallstreet-online.de/dyn/community/thread.html?th…
      Avatar
      schrieb am 09.07.07 20:12:11
      Beitrag Nr. 308 ()
      July 9, 2007 - 6:00 AM EST

      close Email this News Article
      Your Name
      Your Email
      Friend's Name
      Friend's Email
      Receive Copy: yes

      DNAG 0.0077 -0.0003

      Today 5d 1m 3m 1y 5y 10y



      DNAPrint(R) Genomics Announces Acceptance of Studies for Publication
      DNAPrint® Genomics (OTCBB: DNAG), which holds two patents and has seven patent applications pending related to genetic markers, today announced that two studies performed by Company Founder and Chief Science Officer Tony Frudakis, Ph.D., will be published in peer reviewed scientific journals in the coming months.

      "Multilocus OCA2 Genotypes Specify Human Iris Colors," which describes the identification of numerous new OCA2 single nucleotide polymorphism (SNP) associations with iris color and how they can be used together to predict iris color from DNA, will be published in the journal Human Genetics, a respected peer-review journal which publishes the latest research in the field.

      The methods for making these predictions are part of the Company's patent-pending platform for empirically relating genotypes to phenotypes.

      According to one reviewer, the manuscript "illustrates: 1) fine-phenotyping of a complex trait helps dissect the genetic factors that influence the trait; 2) simplistic interpretations for many traits will arise if the scientific community limits its studies of loci to a few associated SNPs and haplotypes." Another reviewer stated that "...this is an interesting paper. OCA2 and iris pigmentation is a great model for studying the effects of genetic variation on a complex trait."

      DNAPrint's ancestry technology was crucial for identifying SNPs truly associated with iris color, as opposed to those merely correlated with iris color due to ancestry informativeness (since ancestry is itself correlated with iris color). In addition, the Company's patented Haploscope software system was crucial for identifying the most informative haplotypes.

      Described for the first time in this manuscript, the method is also described in more detail in a textbook written by Dr. Frudakis to be released later in 2007.

      Another article by Dr. Frudakis that describes a polymorphism associated mainly with Lipitor®-induced myalgia, originally scheduled for publication in November 2006 in the scientific journal Pharmacogenetics and Genomics, will now be published in August 2007. The journal gave no reason for the delay in publication.

      Dr. Frudakis founded the company that eventually became DNAPrint® in 1998, serving as its president and chief executive officer. Prior to this, Dr. Frudakis was a research scientist for Corixa Corporation. In all, his work has resulted in a patent portfolio for over 350 unique genes and two products. Dr. Frudakis is a Phi Beta Kappa, magna cum laude graduate of the University of California Irvine where he received a bachelor's degree in biological sciences. His doctorate in molecular and cell biology is from the University of California Berkeley. Today, Dr. Frudakis is the Chief Science Officer, Director and founder of the company. Mr. Richard Gabriel has assumed the role of President and Chief Executive Officer.

      About DNAPrint(TM) Genomics, Inc.

      DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

      Company Contact:
      Richard Gabriel
      CEO and President
      941-366-3400
      -or-
      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848





      Source: Market Wire (July 9, 2007 - 6:00 AM EST)
      Avatar
      schrieb am 09.07.07 20:35:17
      Beitrag Nr. 309 ()
      Antwort auf Beitrag Nr.: 30.598.159 von Laffel-2 am 09.07.07 20:12:11Manno!

      Ne weitere Fluff-News!!

      Oder was kannst Du da rauslesen?

      Wenn nicht bald was Richtiges(!) kommt, z.B. M2GEN, dann wird`s ab November finanziell so richtig eng.

      Da hilft dann auch kein Cheerleading mehr, dann muss Butter zum Käse und ein Messer zum Fisch!
      Hoffentlich haben sie wenigstens Eines von Beiden!?!
      Avatar
      schrieb am 02.08.07 12:53:07
      Beitrag Nr. 310 ()
      DNAPrint(R) Genomics Reaches Payment Agreement With Dutchess Private Equities Fund, Ltd.
      DNAPrint® Genomics (OTCBB: DNAG) today announced that it has reached a payment agreement with Dutchess Private Equities Fund, Ltd. ("Dutchess") whereby approximately $6 million in notes and incentive debentures may be paid in full by the issuance of stock and warrants in connection with a proposed spin-off of DNAPrint's wholly owned subsidiary, DNAPrint® Pharmaceuticals, Inc. ("Pharmaceuticals").

      Under the terms of the agreement, following the spin-off, Pharmaceuticals would issue up to 2 million shares of Pharmaceuticals' common stock to Dutchess as payment for amounts due under certain notes that were made by DNAPrint® Genomics. As full repayment for the Incentive Debentures, the Registrant would also issue a warrant for 2,000,000 shares of Pharmaceuticals' common stock to Dutchess which could be exercised at an exercise price of $0.01 per share (expiring July 31, 2012) If the balance on the Incentives Debentures at the time of the spin-off is less than $2,000,000, then DNAPrint will be deemed to have made a principal payment on the Notes in the amount of the shortfall. In order to complete the spin-off, Dutchess has agreed to release all the pharmaceutical, diagnostic and associated assets in exchange for the shares of Pharmaceuticals' common stock.

      Effective immediately and until such time that the notes and incentive debentures are paid in full, the agreement calls for DNAPrint® Genomics, Inc. to pay Dutchess the sum of 80% of the royalty income generated by Pharmaceuticals within 45 days after the end of each calendar quarter, and 4% of all other cash received by DNAPrint® Genomics, Inc., from sales of goods or services during the preceding calendar quarter. All of these payments are credited towards the retirement of the debt.

      "We are genuinely pleased to reach this agreement with Dutchess, which could settle its DNAPrint® Genomics debt in full with the planned spin-off of the DNAPrint® Pharmaceuticals division and help to ensure the stability of the parent Company's finances," stated President and Chief Executive Officer Richard Gabriel.

      About DNAPrint(TM) Genomics, Inc.

      DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

      Company Contact:
      Richard Gabriel
      CEO and President
      941-366-3400
      -or-
      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848


      Source: Market Wire (July 31, 2007 - 6:00 AM EST)

      News by QuoteMedia
      www.quotemedia.com
      Avatar
      schrieb am 06.08.07 23:24:24
      Beitrag Nr. 311 ()
      dnag krebst wieder am ATL.......

      .....der Titel ist in sofern interessant, weil das ein Lehrstück ist, wie man Aktionäre enteignet. Das letzte mal haben sie einen Resplit 1:20 gemacht und der Kurs ist danach über 90% eingebrochen. Das können sie nicht noch einmal durchziehen. Jetzt machen sie den letzten Broschen wieder Hoffnung, indem sie das operative Geschäft durch Neuemission ausgliedern. dnag bekommt dafür 6mio in die Kasse. Dann kann der verrückte Professor dort wieder ein paar Monate weiter seine Hobbyforschung betreiben. Das "neue" Unternehmen wird nach IPO auch wieder 90% einbrechen.


      Benn
      Avatar
      schrieb am 08.08.07 12:37:21
      Beitrag Nr. 312 ()
      21:44:50 0,0068 10000
      21:27:58 0,0067 2000000 :eek: :eek:
      21:27:04 0,0066 200000
      21:26:59 0,0066 94410
      21:26:12 0,0065 150000

      Tut sich da was in Kürze?
      Avatar
      schrieb am 08.08.07 12:54:11
      Beitrag Nr. 313 ()
      Antwort auf Beitrag Nr.: 31.077.511 von Laffel-2 am 08.08.07 12:37:21Laffel, da steckt nichts Tiefgründigeres dahinter!

      Coffee880 hat seinen 3mio shares weiter 2mio hinzugefügt; er ist kein Insider, sondern nur ein "normaler" Shareholder, der aufgrund seines Bauchgefühls nachgekauft hat.

      Quelle aus ihub (gestern Abend):
      "Please add 2,000,000 more shares to coffee880's 3,000,000 share count for a new total of 5,000,000 (long for years to come)."
      Avatar
      schrieb am 08.08.07 12:56:44
      Beitrag Nr. 314 ()
      Antwort auf Beitrag Nr.: 31.077.783 von Michiko am 08.08.07 12:54:11Naja, vielleicht hat der ja mehr Gefühl im Bauch als wir :laugh: :D

      Man kann es nur hoffen
      Avatar
      schrieb am 10.10.07 05:47:58
      Beitrag Nr. 315 ()
      Antwort auf Beitrag Nr.: 31.077.830 von Laffel-2 am 08.08.07 12:56:44DNAPrint(R) Genomics and Bioserve Form Strategic Alliance to Provide Clinical Patient Samples Tagged With Genetic Ancestry Data
      BioServe's Fully Annotated Clinical Samples Across Many Diseases to Be Tagged With Ancestry Information Using DNAPrint's Genetic Ancestry Tests
      DNAPrint® Genomics, Inc. (OTCBB: DNAG) today announced the formation of a strategic alliance with BioServe to provide biomedical researchers with clinical DNA samples that for the first time will include genetic ancestry data for each sample. With the added dimension of ancestry information to clinical samples, medical researchers will be able to determine whether certain biological markers are artifacts of genetic ancestry or are true markers for a disease or drug response in a disease. To create the genetic ancestry data, DNAPrint® Genomics will analyze and categorize BioServe's Global Repository® of nearly 600,000 human biological samples using its ANCESTRYbyDNA(TM) validated genetic ancestry test.

      "Our relationship with BioServe is highly synergistic. Both companies believe that any epidemiological program will be more productive with access to high quality validated clinical samples that have been effectively categorized across a validated genetic ancestry platform," said Richard Gabriel, CEO and President of DNAPrint® Genomics. "By removing the question of ancestry from a clinical sample researchers can more readily evaluate which medicines will produce side effects within certain ethnic groups, and which medicines will work for the widest spectrum of a population."

      "Through this partnership with DNAPrint Genomics we can provide the medical research community with the best defined clinical sample set in the world," said Dr. Kevin Krenitsky, CEO of BioServe. "Additionally, we are able to uniquely support the application of our samples with services that include sample extraction and preparation, genotyping, and gene expression. Now that we are able to add the genetic ancestry component to our samples, a new layer of sample data quality and analysis can be provided that was not previously available to researchers."

      Both companies are also capable of providing genotyping services, and between the two companies the following platforms are available: Beckman Ultra High Throughput SNP Platform, Illumina SNP Golden Gate, and Sequenom iPLEX. In addition, several gene RNA expression analysis platforms are available including Differential Expression Pattern Display Technology which has an RNA expression sensitivity 10 to 100 times greater than either of Affymetrix or Illumina gene expression profile technologies.

      DNAPrint(TM) Genomics, Inc.

      DNAPrint(TM) Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

      About BioServe

      BioServe (www.bioserve.com) is a leader in the processing, development, and validation of diagnostic tests for the practice of personalized, predictive and preventive medicine. Leading pharma, biotech and diagnostic firms collaborate with BioServe to identify and validate markers that cause disease while correlating clinical and molecular data to develop new diagnostic tests promoting wellness around the world. BioServe offers the Global Repository®, a growing library of over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients from four continents. Leveraging BioServe's robust genomic analytical services, technology, Global Repository and CLIA-certified laboratory, collaborators gain a complete, highly efficient platform for processing diagnostic test results and identifying genomic markers for powerful new assays. BioServe has headquarters in Beltsville, MD and Hyderabad, India. For more information please visit www.bioserve.com, e-mail info@bioserve.com or call 301-470-3362.

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

      Company Contact:
      Richard Gabriel
      CEO and President
      941-366-3400

      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848
      Avatar
      schrieb am 11.10.07 07:09:15
      Beitrag Nr. 316 ()
      DNAPrint Genomics to Present at Valuerich Small-Cap Financial Expo
      DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that Chief Executive Officer and President Richard Gabriel will present an overview of the Company to analysts at the ValueRich Small-Cap Financial Expo on Thursday, Oct. 18, 2007 at 1:35 p.m. eastern time. The expo will be held at the W New York Hotel, 541 Lexington Avenue in New York City.

      During the 20-minute presentation, Mr. Gabriel will provide an overview of the Company and discuss its goals and outlook for the future. A webcast of the presentation will be available for 180 days after the show at http://www.ivaluerich.com/expo or on the Company's website at www.dnaprint.com.

      About DNAPrint Genomics, Inc.

      DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

      Company Contact:
      Richard Gabriel
      CEO and President
      941 366-3400
      -or-
      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848
      Avatar
      schrieb am 12.10.07 17:57:52
      Beitrag Nr. 317 ()
      Auch heute wieder der Beweis für das Vertrauen in DNAG. Da wird bei jeder Kurserholung nur geschüttet. Bei dem geringen Handelsvolumen ein mühsames Geschäft für die Verkäufer, die da Schlange stehen.

      Benn
      Avatar
      schrieb am 12.10.07 18:33:22
      Beitrag Nr. 318 ()
      Antwort auf Beitrag Nr.: 31.960.124 von benn1 am 12.10.07 17:57:52Bennilein, was redest Du denn da?

      Schau Dir mal die Time&Sales an und rechne mal zusammen, was die Umsätze im bid sind (Verkäufe) und die im ask (Käufe)!

      Time & Sales most recent next page
      Rec. Time Action Price Volume
      11:16:42 AM Trade 0.006 10000
      10:58:34 AM Trade 0.007 9500
      10:58:00 AM Trade 0.007 500
      10:55:52 AM Trade 0.007 14500
      10:55:30 AM Trade 0.007 500
      10:48:32 AM Ask 0.007 10000
      10:48:32 AM Bid 0.006 5000
      10:48:28 AM Trade 0.007 5000
      10:46:42 AM Trade 0.007 120000
      10:46:42 AM Bid 0.007 5000
      10:18:52 AM Trade 0.0073 12000
      10:18:26 AM Trade 0.0072 43500
      10:18:26 AM Trade 0.0072 52900
      10:18:26 AM Trade 0.0073 125000
      10:17:56 AM Trade 0.0073 38000
      10:13:02 AM Trade 0.0072 7100
      10:13:00 AM Trade 0.0073 7100
      10:03:22 AM Trade 0.007 30000
      10:03:22 AM Bid 0.007 10000
      10:03:22 AM Ask 0.0073 5000
      10:02:22 AM Trade 0.007 10000
      10:02:16 AM Trade 0.007 67000
      10:00:16 AM Trade 0.007 100000
      9:59:56 AM Trade 0.007 5000
      9:59:44 AM Trade 0.007 5000
      9:59:42 AM Ask 0.007 5000
      9:59:38 AM Bid 0.0065 5000
      9:36:22 AM Trade 0.007 50000
      9:36:22 AM Trade 0.007 10000
      9:34:40 AM Bid 0.006 10000
      Avatar
      schrieb am 16.10.07 21:35:11
      Beitrag Nr. 319 ()


      Sieht doch sehr gut aus ;)
      Avatar
      schrieb am 18.10.07 14:42:59
      Beitrag Nr. 320 ()
      Börse

      NASDAQ OTC BB

      Aktuell

      0,01 USD

      Zeit

      17.10.07 21:59

      Diff. Vortag

      +23,46 %

      Tages-Vol.

      275.331,27

      Gehandelte Stück

      26 Mio.
      Avatar
      schrieb am 16.11.07 15:19:26
      Beitrag Nr. 321 ()
      DNAPrint(R) Genomics and Beckman Coulter Sign Sales and Marketing Agreement for DNAWitness(TM) and AncestryByDNA(TM)
      DNAWitness(TM) Kits Along With SNPStream(R) Genotyping Systems Offered to the Forensics Community
      DNAPrint® Genomics, Inc. (OTCBB: DNAG) today announced that it has entered into a sales and marketing agreement with Beckman Coulter, Inc., of Fullerton, CA, around DNAPrint's proprietary AncestryByDNA(TM) and DNAWitness(TM) technologies, utilizing Beckman Coulter's SNPStream® Genotyping Systems.

      "As a primary focus, DNAPrint® can provide detectives with the new DNAWitness(TM) descriptor kit that their own crime labs can run," said Richard Gabriel, CEO and President of DNAPrint® Genomics, Inc.

      DNAPrint's sophisticated Ancestry DNA technology can determine genetic ancestry and provide law enforcement a "fuzzy photograph" of an individual from a DNA sample.

      Forensic investigators can use the technology to acquire a description of a suspect or to help them identify unknown victims. "Crime labs or law enforcement agencies can purchase the SNPStream® from either company. It is similar to the pharmaceutical product called 'PharmaID(TM)', which is a high performance technology of validated DNA testing and identification used to predict drug reactions in certain population groups," said Mr. Gabriel. "Forensics, however, is our primary focus."

      Statistics from US Department of Justice indicate that major cities can have 5,000 to 10,000 unsolved murders, dating as far back as 1960. Mr. Gabriel noted, "In 1960, this technology was science fiction. Today we are using it to arrest dangerous criminals -- repeat murderers, rapists and child molesters -- and to free innocent people who were incarcerated by a wrongful conviction.

      "Because of the unconscionable backlog of nearly a half million untested rape kits and entries in the national CODIS system, criminals are free to continue their terror. Victims' rights remain frozen, due to lack of funding to acquire the now-available technology to solve a majority of these crimes. Today, DNAPrint® can help forensic laboratories across the globe to reach beyond CODIS and utilize these powerful technologies," Mr. Gabriel concluded.

      "DNAWitness(TM) has been used in nearly 200 cases across the U.S., Great Britain and Canada. Many of these cases would go unsolved because there are no credible witnesses to testify on the victim's behalf or there are no reliable descriptions of the victim's remains," said Dr. Tony Frudakis, Founder and Chief Scientific Officer of DNAPrint® Genomics, Inc. "Now DNAWitness(TM) Kits and SNPStream® Genotyping Systems are easily available to every forensic laboratory across the globe. We are very excited about this new relationship to broaden the use of DNAWitness(TM) technologies in the forensic and detective communities."

      "Using DNAWitness(TM), investigators have changed the primary direction of investigations, saving time and money, and lessening the risk of the suspect committing additional crimes," said Dr. Mathew Thomas, a Senior Scientist and Laboratory Manager of DNAPrint® Genomics, Inc. "Our technology can significantly narrow the field of suspects, leaving investigators to more thoroughly investigate the substantial credible leads."

      About DNAPrint® Genomics, Inc.

      DNAPrint® Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint® is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWitness(TM), RETINOME(TM), AncestryByDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

      Forward-Looking Statements

      All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint® Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

      Company Contact:
      Richard Gabriel
      CEO and President
      941-366-3400
      -or-
      Ron Stabiner
      The Wall Street Group, Inc.
      212-888-4848


      Source: Marketwire (November 15, 2007 - 7:30 AM EST)

      News by QuoteMedia
      Avatar
      schrieb am 26.11.07 23:55:02
      Beitrag Nr. 322 ()
      Also der "Frosch" bei InvestorsHub gefällt mir.
      Der stellt die richtigen Fragen. :-))

      Benn
      Avatar
      schrieb am 29.11.07 20:20:17
      Beitrag Nr. 323 ()
      DNAG ist ja einfach Klasse. Heute morgen haben sie schon mit einem neuen 52Wochentief eröffnet. Börse hat ja nicht unbedingt etwas mit Wirtschaft zu tun, aber auch Die (ich meine Beide hehe) können sich nicht den Fundamentals auf Dauer entziehen.

      Die Frage bei DNAG ist nicht ob, sondern wann sie vom Kurszettel verschwinden.


      Benn
      Avatar
      schrieb am 06.12.07 13:41:10
      Beitrag Nr. 324 ()
      Michiko,

      was ist mit unserer einstigen Perle los?
      Ich hatte bei 0,005 noch einmal 1M aufgestockt.
      und nun das.

      hvs1
      Avatar
      schrieb am 06.12.07 15:24:03
      Beitrag Nr. 325 ()
      Antwort auf Beitrag Nr.: 32.682.991 von hvs1 am 06.12.07 13:41:10hvs1,

      für diesen Abfall gibt es mehrere Erklärungsmöglichkeiten, und die sind alle wenig zufriedenstellend oder beruhigend.

      Vordergründig: Die Amis betreiben Taxloss-selling um die Verluste steuerlich mit Gewinnen aus anderen Engagements zu verrechnen.
      Das allein erklärt aber wenig.

      Hintergründiger: Die Firma hat vor einigen Monaten erklärt, dass sie sich intensiv um Finanzinvestoren kümmern will und sich auch heftig darum bemüht. Keinesfalls sollten die laufenden Geschäfte aus weiteren Aktienverkäufen (Dilution) bezahlt werden. Auch eine IPO von DNAPP war im Gespräch (DNAPrint-Pharma), vielleicht sogar an der EUREX. Richard Gabriel war diesbezüglich (mehrfach?) hier in Euroland.

      In der Zwischenzeit hat man jetzt eine ganze Weile nichts mehr offiziell von der Company gehört. In AMI-Land wurde das gerne als sogenannte Quiet-Period interpretiert, eine Zeit, in der wichtige Veränderungen getätigt werden, die aber noch nicht an die Öffentlichkeit dringen dürfen.

      Inzwischen ist es mit der Geduld der amerikanischen shareholder vorbei. Und wenn dann noch der Finanzier Dutchess weitere DNAG-shares auf den Markt wirft, also die Dilution gerade wieder weitergeht, dann bedeutet das, dass wir noch ein gutes Stück weiter runter gehen können.

      Bei den Amis scheinen die Nerven blank zu liegen. Ich habe das jetzt mehrfach im Ihub-Board bemerkt: Langjährige Shareholder ziehen sich frustriert zurück, negative Kommentare nehmen zu.
      Und was mich besonders irritiert: Die Moderatoren versuchen, die Meinungsäußerungen massiv zu unterdrücken. Dort herrscht inzwischen eine regelrechte Zensur.
      Meine letzten (kritischen) Beiträge dort wurden fast ausnahmlos gelöscht; inzwischen bin ich sogar befristet rausgeflogen.

      Also: Wenn nicht bald was grundlegend Positives kommt (nicht nur so ne weitere Fluff-PR), dann hat benn1 mit seinen Prognosen absolut recht behalten.

      Das mit Deinen zusätzlichen 1 Mio shares: Hoffentlich habe ich Dich nicht da rein getrieben.

      Gruß Michiko
      Avatar
      schrieb am 06.12.07 17:01:26
      Beitrag Nr. 326 ()
      Michiko,

      mach Dir bitte keine Gedanken.Jeder ist für sich selber verantwortlich.
      Ich kann mir einfach nicht vorstellen,daß die kaputt gehen,bei den
      Patenten die die haben.
      Bist Du selbst noch mit ca. 1M drin?

      Gruß hvs1
      Avatar
      schrieb am 06.12.07 17:10:38
      Beitrag Nr. 327 ()
      Antwort auf Beitrag Nr.: 32.685.887 von hvs1 am 06.12.07 17:01:26hvs1,

      yep!

      Aber es schüttelt mich hin und her: Jetzt nochmal extrem billig nachkaufen und alles riskieren oder raus mit Schrecken und Ende :confused:
      Avatar
      schrieb am 06.12.07 17:35:56
      Beitrag Nr. 328 ()
      Michiko,

      bitte die Ruhe bewahren.
      Ich bin mit Euro ca. 40.000,- in Silex Systems,Uranium One
      Und Beijing cap Land eingestiegen.
      Sowie ich sie gekauft hatte,sind alle gen Süden gegangen.
      Zur Zeit ca. Verlust 5.000,- in 10 Tagen.Ich werde trotzdem nachkaufen auch bei DNAG.

      Gruß hvs1
      Avatar
      schrieb am 10.12.07 22:46:25
      Beitrag Nr. 329 ()
      Auch heute wieder nahe dem ATL geschlossen.

      Die Umsätze sind natürlich dünn, aber doch in einer Höhe die vermuten lässt, das da gerade die Hoffnung stirbt. Immerhin über 5Mio Stück.


      Benn
      Avatar
      schrieb am 11.12.07 14:11:52
      Beitrag Nr. 330 ()
      Antwort auf Beitrag Nr.: 32.720.982 von benn1 am 10.12.07 22:46:25Schau Dir mal den Tagesverlauf an. Sieht nicht nach Depression aus.

      Avatar
      schrieb am 11.12.07 15:29:59
      Beitrag Nr. 331 ()
      Michiko,
      sehe ich auch so.

      hvs1
      Avatar
      schrieb am 20.12.07 23:00:19
      Beitrag Nr. 332 ()
      DNAG hat seinen Aktionären heute ein Weihnachtsgeschenk gemacht - ein neues ATL. Auf Jahresbasis nur -50%.

      Das bedeutet natürlich nicht, dass sie sich nicht noch einmal halbieren können.

      Ho Ho Ho

      Benn
      Avatar
      schrieb am 31.12.07 22:07:03
      Beitrag Nr. 333 ()
      Antwort auf Beitrag Nr.: 32.833.009 von benn1 am 20.12.07 23:00:19Intraday am letzten Handelstag noch ein neues ATL gemacht. Es erübrigt sich bei DNAG einen guten Rutsch zu wünschen. Da ist das ja Programm. :->

      Benn
      Avatar
      schrieb am 09.01.08 09:43:12
      Beitrag Nr. 334 ()
      Hallo Michiko,

      bist Du noch an Bord?
      Unser Baby geht ja ganz schön ab,leider in die verkehrte Richtung.
      Wäre schön was von Dir zu hören.Wünsche Dir ein frohes neues Jahr.

      Gruß hvs1
      Avatar
      schrieb am 09.01.08 18:05:33
      Beitrag Nr. 335 ()
      Antwort auf Beitrag Nr.: 32.989.163 von hvs1 am 09.01.08 09:43:12hvs1, meine Antwort findest du dort:

      http://www.wallstreet-online.de/dyn/community/thread.html?th…


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.

      Investoren beobachten auch:

      WertpapierPerf. %
      +0,05
      +10,53
      +1,23
      -3,57
      -2,68
      -2,45
      -4,47
      -4,69
      -0,59
      +1,28

      Meistdiskutiert

      WertpapierBeiträge
      116
      74
      54
      49
      37
      37
      36
      34
      33
      32
      DNAG-PRINT